Introduction {#s1}
============

Autoreactive T and B lymphocytes are controlled by regulation of population sizes and pathogenicity through clonal deletion ([@bib8]), clonal anergy ([@bib59]) and regulatory T cells ([@bib66]). Through broadly-reactive pattern recognition receptors (PRRs) ([@bib33]; [@bib53]), innate immunity protects host against infections by both direct effector function and, indirectly, by induction of adaptive immunity ([@bib47]; [@bib48]; [@bib85]; [@bib62]). Since innate immune responses triggered by host components can also cause fatal tissue damage ([@bib75]; [@bib10]), it must be properly regulated to protect hosts against self-destruction. Although a number of mechanisms have been proposed to prevent self-destructive innate effector functions ([@bib49]; [@bib50]; [@bib52]; [@bib45]; [@bib77]), it is less clear if population sizes of innate effectors are suppressed to limit self-destruction.

The significance of protective self-tolerance mechanisms in adaptive immunity are revealed only when they have gone awry. For example, the significance of clonal deletion was elucidated when it was prevented by blocking either costimulation or antigen-expression in the thymus ([@bib2]; [@bib21]), while mice with Foxp3 mutation informed us of the consequence of defective regulatory T cells ([@bib29]; [@bib20]). Since removal of the forbidden autoreactive T and B cells is achieved during T and B cell development ([@bib57]; [@bib71]; [@bib39]), it is intriguing whether certain parallel mechanisms in innate immunity might also remain to be uncovered through genetic inactivation of key regulators in development of innate effector cells.

The hematopoietic system is among the best characterized of all tissue/systems in mammalians, with cell types and lineages clearly defined in the context of developmental stages and localization ([@bib54]; [@bib84]). Hematopoiesis in bone marrow (BM) is responsible for generation of major lineages of innate effectors, including NK cells, granulocytes, monocytes and dendritic cells. While genetic switch in generation of innate immune system has been identified ([@bib84]), we are not aware of defects that predispose host to innate immune attack through increasing population sizes of self-destructive innate effectors.

The mammalian target of rapamycin (mTOR) pathway, which couples energy and nutrient abundance to the execution of cell growth and division, has emerged as a major regulator of hematopoiesis. Thus, activation of mTOR complex 1 (mTORC1) by deleting *Tsc1*, which encodes a negative regulator for mTORC1 ([@bib32]), causes loss of hematopoietic stem cell (HSC) function and renders mice prone to leukemiogenesis in conjunction with loss of tumor suppressor *Pten* ([@bib88]; [@bib89]; [@bib9]). More recently, two groups reported that deletion of *Rptor*, which encodes a critical component of mTORC1 ([@bib27]; [@bib37]), dramatically perturbed hematopoiesis in mice ([@bib30]; [@bib34]), as evidenced by defects in production of mature lymphoid and myeloid cells. Remarkably, cells with CD11b^+^ Gr-1^-^ surface markers massively accumulated in BM following *Rptor* deletion in HSCs ([@bib30]; [@bib34]). The nature of this population and consequences of their accumulation, however, remains a mystery.

Here we systematically analyzed the gene expression signature, cell surface markers, morphology and functions of the CD11b^+^Gr-1^-^ population in the *Rptor*-deficient BM and other organs and sought for their physiological counterpart in the normal mice. We found that these cells can be identified in both normal and *Rptor*-deficient hosts by CD3^-^B220^-^NK1.1^-^Ter119^-^ CD11c^low/-^CD115^-^F4/80^low/-^Gr-1^-^ CD11b^+^PD-L1^+^ markers, lymphoid morphology and actively transcribed *Ig* loci. Interestingly, these cells broadly express essentially all TLRs along with many other pattern recognition receptors and mount a greatly exacerbated response to all TLR ligands tested. We name this population IMLEC for innate myelolymphoblastoid effector cell that can be derived from common myeloid progenitors. Because their expansion and broad distribution render the host vulnerable to TLR ligands, we suggest that mTORC1-mediated repression of IMLEC expansion represents a new mechanism of immune tolerance in the innate immunity. Our study also raises an intriguing perspective that while repressing mTOR over-activation suppresses leukemia, a functional mTORC1 must be maintained to limit generation of IMLECs to avoid innate immune destruction.

Results {#s2}
=======

Raptor suppresses accumulation of a previously uncharacterized subset of leukocytes with features of both myeloid and lymphoid cells {#s2-1}
------------------------------------------------------------------------------------------------------------------------------------

As germline deletion of *Rptor* (which encode the Raptor protein) is embryonic-lethal, we crossed mice harboring homozygous loxp-flanked *Rptor* exon 6 ([@bib63]) to those with interferon-inducible *Mx1-Cre* recombinase transgene, which allows inducible deletion of target genes effectively in the hematopoietic system upon treatment of interferon or its inducers ([@bib42]). We treated the 6--8 weeks old *Rptor ^F/F^* and *Rptor ^F/F^*,*Mx1-Cre* mice with polyinosinic: polycytidylic acid (pIpC) every other day for 2 weeks to induce the deletion of *Rptor*. Hereafter, we refer to the pIpC-treated *Rptor ^F/F^* mice as Ctrl (control) mice, while the *Rptor ^F/F^, Mx1-Cre* mice as cKO (conditional knockout) mice ([Figure 1A](#fig1){ref-type="fig"} and [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). As has been reported by others ([@bib30]; [@bib34]), *Rptor* deletion causes broad defects in all lineages of hematopoietic cells (see also [Figure 1---figure supplements 1](#fig1s1){ref-type="fig"}, [2](#fig1s2){ref-type="fig"} and [3](#fig1s3){ref-type="fig"}). However, the number of hematopoietic stem/progenitor cells (HSPCs) increased ([Figure 1---figure supplement 4](#fig1s4){ref-type="fig"}). Most notably, CD11b^+^ Gr-1^-^ cells, which amount to nearly 50% of BM cells in our model, emerge at the expense of CD11b^+^ Gr-1^+^ granulocytes from the cKO mice ([Figure 1B,C](#fig1){ref-type="fig"}). Importantly, we also observed the massive accumulation of CD11b^+^Gr-1^-^ cells in the BM of *Rptor^F/F^*, *Cre-ER* mice after tamoxifen induced targeted mutation of *Rptor*, which clearly excludes the role of pIpC in the generation of these cells ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}).

![Targeted mutation of *Rptor* in hematopoiesis led to massive accumulation of IMLEC.\
(**A**) Schematic of experimental design. Sex-matched 6--8 weeks old Ctrl (*Rptor ^F/F^*) and cKO (*Rptor ^F/F^, Mx1-Cre*) mice were treated with pIpC for seven times. The phenotypes were analyzed on day 7 or day 30 after the complement of pIpC treatment. (**B**) Representative flow cytometric analysis of myeloid cells from mice BM by CD11b and Gr-1 on day seven after pIpC treatment. Similar data were obtained on day 30. (**C**) Frequencies of various hematopoietic cell populations in BM based on CD11b and Gr-1 markers. n = 7 for Ctrl mice; n = 9 for cKO mice. Data are pooled from three independent experiments. (**D**) Expansion of lymphoblast population in cKO BM revealed by histology. Left, H&E staining showing prominence of cells with lymphoid morphology in the cKO BM; Right, normal BM histology from Ctrl mouse showing normal myeloid and erythroid lineages. Scale bar, 20 μm. (**E**) Expansion of lymphoblast revealed by cytology. Left, cytological preparation of BM smear from cKO mouse showing preponderance of lymphocytes (short arrows) and severe depletion of myeloid and erythroid lineages. There were some promyelocytes and myelocytes present (larger cells) but no mature neutrophils. Right, normal cytological preparation of BM from Ctrl mouse. There were numerous erythroid precursors with intensely basophilic, condensed chromatin (arrowheads) and a few lymphocytes (short arrow) with less condensed chromatin. Additionally, in Ctrl BM there were numerous mature neutrophils (ringed nucleus with constrictions) which were severely depleted in the cKO mouse. Scale bar, 10 μm. (**F**) Giemsa staining of FACS-sorted *Rptor*-deficient CD11b^+^Gr-1^-^ BM cells. Scale bar, 10 μm. Similar morphology was observed in three independent experiments. (**G**) Principal component analysis (PCA) of gene expression in CD11b^+^ Gr-1^-^ BM cells (IMLECs) and other hematopoietic cells. Numbers along axes indicate relative scaling of the principal variables. RNA-seq data from IMLECs obtained in our study were compared with those deposited in public database by others. Datasets are from known lymphoid (Pro-B, Pre-B, Naïve B, CD4 T, CD8 T, Treg and NK) or myeloid (macrophage, dendritic cell, granulocyte, neutrophil, eosinophil, basophil and erythrocyte) subsets.](elife-32497-fig1){#fig1}

The CD11b^+^ Gr-1^-^ cells were smaller and had reduced granularity when compared to CD11b^+^ Gr-1^+^ granulocytes, but were larger and more granular than the CD11b^-^ Gr-1^-^ cells ([Figure 1---figure supplement 2E,F](#fig1s2){ref-type="fig"}). Surprisingly, despite the expression of myeloid marker CD11b on the expanded population of BM cells, histological analysis of BM section revealed pervasive expansion of lymphoblastoid cells ([Figure 1D](#fig1){ref-type="fig"}). The cKO BM contained markedly decreased erythroid and myeloid lineage cells and markedly increased lymphocytes. Lymphocytes were predominantly small-to-medium sized and had normal cytological features. There was also an increased population of large blast-like cells with prominent nucleoli and perinuclear clearing resembling lymphoblasts. Plasma cells were present in small numbers. The myeloid: erythroid ratio was within normal range (3.04) but the overall number of erythroid and myeloid cells was very low. In particular, very few erythroid cells were present. In the myeloid lineage there was also maturation disruption since immature ring form neutrophils (neutrophilic metamyelocytes) predominated over mature neutrophils (condensed chromatin) ([Figure 1D](#fig1){ref-type="fig"}). Giemsa staining of BM smear revealed a massively increased lymphoblast population and severe depletion of both immature erythroid cells and granulocytes in the cKO mice ([Figure 1E](#fig1){ref-type="fig"}). These cells were replaced by cells with prominent nucleoli and perinuclear clearing resembling lymphoblasts. To confirm that the lymphoblasts were the CD11b^+^ Gr-1^-^ cells identified by flow cytometry in the cKO BM ([Figure 1B,C](#fig1){ref-type="fig"}), we FACS-sorted the subset based on CD11b^+^ Gr-1^-^ surface markers and validated its lymphoid morphology ([Figure 1F](#fig1){ref-type="fig"}).

The spleen was greatly enlarged due to expansion of the follicular centers and periarteriolar sheaths within the splenic white pulp (lymphoid areas) of the cKO mice ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). The expanding white pulp populations consisted of lightly stained, large cells that morphologically resembled germinal center lymphocytes. In some areas, these populations expanded within the marginal zones while in others, they involved the periarteriolar sheaths. The cells had an increased amount of pale eosinophilic cytoplasm and mild pleomorphism with both centroblast-like cells (larger cells with large ovoid nuclei and 1--2 prominent nucleoli per cell) and centrocyte-like cells (smaller cells with cleaved or elongated nuclei and unapparent nucleoli).

Since cells with such combination of morphology and surface markers had not been identified previously, we FACS-sorted the CD11b^+^ Gr-1^-^ cells from the *Rptor* cKO BM and carried out next-generation RNA sequencing (RNA-seq). Using principal component analysis (PCA), we compared gene expression profiles of these CD11b^+^ Gr-1^-^ cKO BM cells with other known subsets of hematopoietic cells, including B cells, T cell subsets, NK cells, myeloid cell subsets, dendritic cells and erythroid cells. This analysis demonstrates that the CD11b^+^Gr-1^-^ cKO BM cells were distinct from all known blood cell types, although they appear to be closely related to B lymphocytes and macrophages ([Figure 1G](#fig1){ref-type="fig"}). We hereafter refer these cells as innate myeloidlymphoblastoid effector cells (IMLECs).

We identified subset specific genes using a threshold of 4-fold changes and an adjusted FDR-adjusted p-value\<0.01. As shown in [Figure 2A](#fig2){ref-type="fig"}, by comparing RNA-seq data-based gene expression signature of all known leukocyte subsets, a unique gene expression signature was identified in the CD11b^+^ Gr-1^-^ cKO BM IMLECs. The signature consists of 48 genes that are up-regulated by more than 4-fold. The 48 genes over expressed in the CD11b^+^ Gr-1^-^ cKO BM IMLECs are listed in [Figure 2B](#fig2){ref-type="fig"}. Among their diverse functions, these genes are involved in intracellular signaling cascades (such as *Arhgap31*, *Rab20*, *Gna12*, *Mink1* and *Prkch*) and metabolic processes (such as *Naga*, *Atf3*, *Aoah*, *Chst14* and *Gns*). The uniqueness of cKO BM IMLEC is also supported by pair-wise comparisons between IMLEC and peritoneal macrophage or other closely related cell types that are prominent in BM ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

![Unique gene signature of *Rptor^-/-^* CD11b^+^ Gr-1^-^ BM IMLECs.\
(**A**) Heat map representing the relative expression levels for indicated population-specific genes. Genes up-regulated for at least 4-fold with FDR-adjusted p-value\<0.01 were considered population-specific. Numbers on right indicate amounts of population-specific genes. (**B**) Heat map representing expression levels of 48 CD11b^+^Gr-1^-^ BM IMLEC-specific genes among indicated populations including macrophage, B precursor, naive B and granulocyte. (**C**) Genome browser display of transcript structure and gene expression quantity for immunoglobulin heavy chain (IgH) complex gene region from indicated populations. For each track, the normalized numbers of aligned reads count or Reads Per Kilobase of transcript per Million mapped RNA (RPKM) are shown in y-axis, while the gene positions for the sterile transcripts are shown in x-axis. Numbers on top indicate the start and end loci on bases along chromosome 12 for specified gene region. Similar profiles of cKO IMLEC were observed in two other samples analyzed. (**D**) mRNA levels of *Rag1* and *Rag2* in cKO CD11b^+^ Gr-1^-^ BM IMLECs in comparison to Ctrl whole BM cells. n = 6 for Ctrl-WBM; n = 8 for IMLEC. Data are pooled from three independent experiments. (**E**) IMLECs did not display immunoglobulin gene rearrangement. FACS-sorted CD11b^+^ Gr-1^-^ cells (IMLECs) from cKO BM were dissected for Ig gene rearrangement patterns of heavy chain (J~H~), light chains *Igk* (J~Lκ~) and *Igl* (J~Lλ~) by PCR. WBM cells from Raptor Ctrl mice were used as positive control. These data have been repeated twice.](elife-32497-fig2){#fig2}

A defining feature of the B cell lineage is activation of *Ig* gene loci, as evidenced by 'sterile' transcripts transcribed from the unarranged loci of Ig heavy chain (*Igh*) and light chains (*Igk* and *Igl*) ([@bib73]). RNA-seq data revealed high levels of sterile transcripts within the *Igh* locus ([Figure 2C](#fig2){ref-type="fig"}) and *Igk* and *Igl* loci ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}) from both B cell lineages and cKO BM IMLECs. This is a significant difference from macrophage, which had no detectable expression of the sterile transcripts, as expected. Another defining feature of developing B-lymphocytes is *Ig* gene rearrangement, a unique mechanism of genetic recombination that occurs only during the early stages of B cell maturation. This process is strictly dependent on recombinases genes *Rag1* ([@bib56]; [@bib69]) and *Rag2* ([@bib72]; [@bib61]). As shown in [Figure 2D](#fig2){ref-type="fig"}, no expression of *Rag1* was detectable by quantitative PCR (qPCR), although a detectable but extremely low level of *Rag2* was observed. Consistent with lack of *Rag1* expression, no gene rearrangement was found in the *Ig* loci ([Figure 2E](#fig2){ref-type="fig"}). Taken together, our data so far demonstrate that Raptor suppresses accumulation of a previously uncharacterized leukocyte subset with features of both myeloid and lymphoid cells.

Characterization of IMLECs in *Rptor* cKO and WT mice {#s2-2}
-----------------------------------------------------

IMLECs identified in the *Rptor* cKO mice did not express surface markers that are used to define other lymphocytes, such as B220 for B cells, CD3 for T cells and NK1.1 for NK cells ([Figure 3A](#fig3){ref-type="fig"}). The high levels of CD11b indicated that these cells are distinct from the recently identified innate lymphoid cells (ILCs) that are CD11b negative ([@bib82]). In addition, they lack surface markers for progenitor cells, such as c-Kit and Sca-1 ([Figure 3A](#fig3){ref-type="fig"}). Although the cKO IMLECs retained a high level of myeloid marker CD11b, they expressed a very low level of F4/80 macrophage marker and lacked CD115 monocyte marker ([Figure 3B](#fig3){ref-type="fig"}). To identify a positive marker for IMLEC, we searched our RNA-seq database for overexpression of genes that encode cell surface CD (cluster of differentiation) markers. Among 317 CD markers ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), the most up-regulated gene in the cKO BM IMLECs over Ctrl whole BM cells was *Cd274* (also called *B7h1* or *Pdl1*). As shown in [Figure 3B](#fig3){ref-type="fig"} and [Figure 3C](#fig3){ref-type="fig"}, PD-L1 was expressed on the vast majority of CD11b^+^ Gr-1^-^ BM cells from *Rptor* cKO mice.

![Identification of IMLEC by cell surface markers in both Raptor cKO and WT mice.\
(**A**) IMLECs do not express surface markers for conventional lymphocytes (CD3, B220 and NK1.1) and stem and progenitor cells (c-Kit and Sca-1). CD11b^+^ Gr-1^-^ IMLECs from Raptor cKO BM were tested for their expression of lymphocytes and progenitor cell markers. These data have been repeated three times. (**B**) IMLECs do not express markers for monocytes and macrophages but surprisingly express high levels of PD-L1. Filled gray areas indicate distributions of fluorescence from stainings by control antibodies. One representative result of at least five experiments is shown. (**C**) *Rptor* deletion causes expansion of Lin^-^ (B220^-^ CD3^-^ Ter119^-^ NK1.1^-^ Gr-1^-^ F4/80^-^ CD115^-^) CD11b^+^ PD-L1^+^ IMLECs in BM. Representative flow staining profiles for BM IMLECs (left) and their abundance summary data (right) are presented. n = 5 for Ctrl BM; n = 5 for cKO BM. (**D**) Lin^-^CD11b^+^ PD-L1^+^ BM IMLECs are CD11c^-/low^. One representative result of two experiments is shown. (**E**) The Lin^-^ CD11b^+^ PD-L1^+^ CD11c^-/low^ IMLECs are found in various lymphoid and non-lymphoid organs from WT mice. mLN, mesenteric lymph nodes; c/i LN, cervical and inguinal lymph nodes. The numbers (Mean ±SD) are summarized abundances of IMLECs among mononuclear cells (MNCs) from 3 WT mice. (**F--H**) *Rptor* deletion caused a broad accumulation of IMLECs in lung (**F**), mesenteric lymph nodes (**G**) and peripheral (cervical and inguinal) lymph nodes (**H**). Results shown are representative of three mice in each group. (**I**) Summary data showing increased IMLECs in the lymphoid and non-lymphoid organs. n = 3 for both groups.](elife-32497-fig3){#fig3}

Based on the above data and availability of robust cell surface markers, we define IMLECs by their expression of CD11b and PD-L1, but lack of major lineage markers for T cells (CD3), B cells (B220), natural killer cells (NK1.1), erythroid cells (Ter119), granulocytes (Gr-1), macrophages and monocytes (F4/80 and CD115). These markers allowed us to search wild-type BM for IMLEC. Interestingly, a clear although small fraction of the Lin^-^ (CD3^-^B220^-^ NK1.1^-^ Ter119^-^ Gr-1^-^ F4/80^-^ CD115^-^) CD11b^+^ BM cells in the Ctrl mice also expressed PD-L1 ([Figure 3C](#fig3){ref-type="fig"}, left panel), although the overall PD-L1 expression level was not as high as that from cKO IMLECs. Following *Rptor* deletion, a robust expansion (approximately 500-fold) of Lin^-^ CD11b^+^ PD-L1^+^ BM IMLECs was observed ([Figure 3C](#fig3){ref-type="fig"}, right panel).

It should be noted that although cKO IMLECs also over-express *Cd11c* gene ([Supplementary file 1](#supp1){ref-type="supplementary-material"}), IMLEC gene expression profiles are distinct from dendritic cell (DC) based on gene signature ([Figure 1G](#fig1){ref-type="fig"} and [Figure 2---figure supplement 1E,F](#fig2s1){ref-type="fig"}). In cKO IMLECs, the CD11c levels were somewhat lower than the PD-L1^-^ DC ([Figure 3D](#fig3){ref-type="fig"}). In WT mice, greater than 90% of Lin^-^CD11b^+^PD-L1^+^ IMLEC in BM, lung and peripheral blood mononuclear cells expressed only low levels of CD11c, while those in spleen and mesenteric lymph nodes consisted of two major subsets: CD11c^high^ and CD11c^low/-^ ([Figure 3E](#fig3){ref-type="fig"}). IMLECs were also found among the leukocytes isolated from lung and in peripheral lymphoid organ ([Figure 3F, G and H](#fig3){ref-type="fig"}), and this population was greatly expanded in the cKO mice ([Figure 3I](#fig3){ref-type="fig"}).

To further confirm that this subset is the IMLEC in normal BM, we FACS-sorted the Lin^-^ (CD3^-^ B220^-^ NK1.1^-^ Ter119^-^ Gr-1^-^ F4/80^-^ CD115^-^) CD11b^+^ PD-L1^+^ cells from wild type (WT) BM and characterized their morphology and levels of sterile *Ig* transcripts. As shown in [Figure 4A](#fig4){ref-type="fig"}, the sorted cells had a lymphoid morphology as did the cKO IMLECs. They also displayed comparable size and granularity as cKO IMLECs ([Figure 4B](#fig4){ref-type="fig"}). Moreover, Lin^-^ CD11b^+^ PD-L1^+^ cells from WT BM expressed sterile transcripts of *Ig* loci identified by RNA-seq ([Figure 4C](#fig4){ref-type="fig"}). Furthermore, subsequent validation of IMLECs in WT BM was undertaken by comparing the expression of other top candidate markers (CD14, CD16) and MHC-I/MHC-II ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), as well as population-specific transcription factors *Mitf*, *Atf3* and *Zdhhc1* ([Figure 4D,E](#fig4){ref-type="fig"}). The largely comparable expression levels of these surface markers and transcription factors between WT and cKO IMLECs provide additional lines of evidence for these cells to be naturally occurring IMLECs. Therefore, a small fraction of normal leukocytes in lymphoid and non-lymphoid tissues have the IMLEC phenotype, and this subset is massively expanded after *Rptor* deletion.

![Comparison of IMLECs identified in both WT and Raptor-deficient BM.\
(**A**) Giemsa staining of Lin^-^ CD11b^+^ PD-L1^+^ IMLECs from WT BM and *Rptor*-cKO BM. One representative result of 3 independent experiments is shown. Scale bar, 10 μm. (**B**) Size and granularity of IMLECs from Raptor Ctrl and cKo BM were evaluated by FSC and SSC, respectively. n = 5 for each group. (**C**) IMLEC from WT BM expresses sterile transcripts from the *Igh* and *Igl* loci. *Ig* transcript levels in macrophage are artificially defined as 1. (**D**) Heat map representing the relative expression levels for indicated population specific transcription factor genes. Genes up-regulated for at least 4-fold with FDR-adjusted p-value\<0.01 were considered population-specific. (**E**) IMLECs from both WT and Raptor-cKO BM exhibit high levels of mRNA transcripts for the specified transcription factors (*Mitf*, *Atf3* and *Zdhhc1*). n = 5 for each group. (**F, G**) Ctrl and cKO IMLECs are non-cycling cells in contrast to Lin^+^ BM cells. (**H, I**) IMLECs are prone to apoptosis based on their binding to Annexin V. Results in (**C**), (**G**) and (**I**) represent one of 2 independent experiments with each involving three mice per group.](elife-32497-fig4){#fig4}

Altered differentiation is responsible for accumulation of IMLECs {#s2-3}
-----------------------------------------------------------------

Theoretically, expansion of IMLECs in cKO BM may be caused by increased proliferation and/or reduced apoptosis. To test this possibility, we analyzed the proliferation of IMLECs by Ki-67 staining and BrdU incorporation. Remarkably, Lin^-^ CD11b^+^ PD-L1^+^ IMLECs from both Raptor Ctrl and cKO BM had much fewer Ki-67^+^ cells ([Figure 4F,G](#fig4){ref-type="fig"}) or BrdU^+^ cells ([Figure 4---figure supplement 1B,C](#fig4s1){ref-type="fig"}) when compared with other lineages. The fact that IMLECs are not proliferating at a higher rate than other BM cell types effectively rules out rapid proliferation as an explanation for IMLECs accumulation in Raptor cKO BM. Likewise, the massive increase of IMLEC in cKO mice over those in the Ctrl mice cannot be due to proliferation, as the percentage of Ki-67^+^ or BrdU^+^ cells is not increased in cKO mice. Furthermore, based on cell surface Annexin V staining, IMLECs from cKO BM were more prone to apoptosis than total lineage^+^ population ([Figure 4H,I](#fig4){ref-type="fig"}) and had apoptosis rate that was comparable to granulocytes, B cells and T cells in BM ([Figure 4---figure supplement 1D,E](#fig4s1){ref-type="fig"}). The pronounced apoptosis also rules out the possibility that increased survival may account for preferential accumulation of IMLECs in cKO mice. The robust apoptosis detected among WT IMLECs likely contributed to the reduced amount of IMLECs in normal BM ([Figure 3C](#fig3){ref-type="fig"}). Consistent with the reduced proliferation and increased apoptosis of IMLECs, our exhaustive efforts to demonstrate self-renewal of IMLEC through transplantation of massive numbers of IMLEC have all been unsuccessful (data not shown).

As an alternative hypothesis, we evaluated whether IMLECs accumulated because of altered differentiation of hematopoietic stem and progenitors (HSPCs). As the first step to test this hypothesis, we evaluated if IMLEC accumulation in cKO BM was cell-intrinsic. Briefly, we mixed either *Rptor^F/F^* or *Rptor^F/F^, Mx1-Cre* (both CD45.2^+^) BM cells with recipient type CD45.1^+^ WT BM cells at a 2:1 ratio. At six weeks after BM transplantation, *Rptor* was deleted from the *Rptor^F/F^, Mx1-Cre* donor-derived cells by pIpC treatment ([Figure 5A](#fig5){ref-type="fig"}). As shown in [Figure 5B](#fig5){ref-type="fig"}, the accumulation of CD11b^+^ Gr-1^-^ IMLECs was intrinsic to *Rptor* ^-/-^ BM cells. Since our earlier data suggested that IMLECs accumulated at the expense of granulocytes ([Figure 1B,C](#fig1){ref-type="fig"}), we tested if granulocytes were converted to IMLECs following *Rptor* deletion. We produced *Rptor^F/F^, Lyz2-Cre^+/+^* mice that should have myeloid lineage-specific deletion of *Rptor*. However, despite the effective deletion of the *Rptor* gene in the granulocytes ([Figure 5C](#fig5){ref-type="fig"}), the percentages of CD11b^+^ Gr-1^+^ granulocytes and CD11b^+^ Gr-1^-^ IMLECs were unchanged ([Figure 5D](#fig5){ref-type="fig"}). These data suggest that accumulation of IMLEC in the cKO mice was not due to trans-differentiation from granulocytes.

![Raptor represses differentiation of IMLEC from CMP.\
(**A, B**) IMLEC accumulation in *Rptor^-/-^* BM is cell autonomous. (**A**) Diagram depicting generation of mixed BM chimera, induction of *Rptor* deletion and analyses for IMLEC. (**B**) In mixed BM chimera mice, IMLEC was accumulated only in the Raptor-deficient hematopoietic cells. Mice were sacrificed and analyzed at 4 weeks post pIpC treatment. CD45.1^+^ and CD45.2^+^ donor-derived BM cells were gated to show the myeloid subsets based on CD11b and Gr-1. Similar data were obtained in three independent experiments, each involving at least three mice per group. (**C, D**) BM IMLECs are not converted from CD11b^+^ Gr-1^-^ granulocytes. (**C**) Genotyping and deletion efficacy. CD11b^+^Gr-1^+^ cells (DP) and CD11b^-^Gr-1^-^ cells (DN) were sorted from BM of KO (*Rptor^F/F^, Lyz2-Cre^+/+^)* mice. Floxed and deleted *Rptor* alleles, as well as *Lyz2-Cre* wild type (WT) and mutated (MT) alleles were confirmed by PCR. (**D**) Efficient deletion of *Rptor* in the CD11b^+^Gr-1^+^ compartment failed to cause IMLEC accumulation. Data shown are representative BM flow profiles of Ctrl mice and those with *Rptor* deletion in the CD11b^+^Gr-1^+^ compartment, depicting distributions of CD11b and Gr-1 markers in adult mice. Similar data have been obtained in three experiments, involving a total of 5 mice per group. (**E, F**) *Rptor^-/-^* LSK, CLP and CMP cells differentiate into IMLECs in vitro. (**E**) Diagram of experimental design. 2 × 10^3^ LSK cells or 5 × 10^4^ CLP or 5 × 10^4^ CMP cells were co-cultured with the OP9 cells for 10 days. (**F**) *Rptor* deletion promoted generation of IMLEC. The CD45.2^+^ leukocytes were gated and analyzed for their expression of CD11b, Gr-1 and PD-L1. Data shown are representative of three independent experiments. (**G, H**) Both LSK and CMP cells differentiate into IMLECs in vivo. (**G**) Diagram of BM cells transplantation. FACS-sorted, Ctrl or cKO LSK cells (5 × 10^4^/mouse) or CMP cells (1.2 × 10^5^/mouse) were injected i.v. to CD45.1 recipient mice which were immediately administrated with five daily pIpC treatments. BM cells were harvested on day seven for FACS analyses. (**H**) *Rptor* deletion promoted differentiation of progenitor cells into IMLEC. Donor-derived CD45.2^+^ BM cells were gated to analyze surface markers CD11b, Gr-1 and PD-L1. Data shown are representative flow profiles from one of 3 independent experiments.](elife-32497-fig5){#fig5}

Next, we use both in vitro co-culture and in vivo BM transplantation to identify the progenitor that may give rise to IMLECs. We co-cultured OP9 stromal cells with FACS-sorted BM LSK (Lin^-^ Sca-1^+^ c-Kit^+^), CMP (Lin^-^ Sca-1^-^ c-Kit^+^ CD34^Medium^ CD16/32^Medium^) and CLP (Lin^-^CD127^+^ Sca-1^Medium^c-Kit^Medium^) populations from Ctrl and cKO mice that had been treated with pIpC ([Figure 5E](#fig5){ref-type="fig"}). As shown in [Figure 5F](#fig5){ref-type="fig"}, both LSK and CMP populations from *Rptor^-/-^* BM gave rise to CD11b^+^ Gr-1^-^ PD-L1^+^ IMLECs. As expected, *Rptor*-sufficient CLPs were not able to give rise to CD11b^+^ myeloid cells. Interestingly, *Rptor*-deficient CLPs generated progenies with a small portion exhibiting immunophenotypes of IMLECs. We also transplanted sorted LSK and CMP populations and induced *Rptor* deletion in the donor cells by treating recipients with pIpC ([Figure 5G](#fig5){ref-type="fig"}) to confirm their ability in giving rise to IMLECs. Due to lack of self-renewal activity of progenitor cells and rapid apoptosis of IMLEC, we used a much shorter timeline than the whole bone marrow transplantation studies in order to capture progenitor-derived IMLEC. As shown in [Figure 5H](#fig5){ref-type="fig"}, deletion of *Rptor* in either LSKs or CMPs was sufficient to induce the generation of CD11b^+^ Gr-1^-^PD-L1^+^ cells in recipients BM. The shorter timeline explained relative paucity of LSK-derived IMLEC when compared with long-term bone marrow transplantation ([Figure 5A,B](#fig5){ref-type="fig"}). As expected, since CMPs do not have self-renewal capability, only a small number of progeny cells were produced. However, since IMLEC can be generated from CLP in vitro, their potential to do so under physiological conditions cannot be ruled out. Taken together, our data demonstrate that the massive accumulation of IMLECs in cKO mice can be caused by altered differentiation of CMPs, although other differentiation pathway cannot be ruled out.

Reduced c-Myb expression is responsible for accumulation of IMLECs {#s2-4}
------------------------------------------------------------------

A previous study demonstrated that heterozygous *Myb* mutation leads to an expansion of BM CD11b^+^Gr-1^-^ cells ([@bib23]). Although expression of PD-L1 was not evaluated in the earlier study, we were intrigued by the possibility that down-regulation of *Myb* may be the underlying mechanism for the massive production of IMLECs. Since both LSKs and CMPs are able to give rise to CD11b^+^ Gr-1^-^ PD-L1^+^ IMLECs, we evaluated expression of c-Myb in both LSK and CMP populations. Indeed, the *Myb* transcripts were significantly reduced in both LSK and CMP populations sorted from *Rptor* cKO mice ([Figure 6A](#fig6){ref-type="fig"}). Moreover, our intracellular staining also revealed reduced levels of c-Myb protein in both LSKs and CMPs from cKO BM ([Figure 6B](#fig6){ref-type="fig"}). Interestingly, induced deletion of c-Myb in mice with homozygous floxed c-Myb (*Myb*^F/F^, *Mx1-Cre*), but not heterozygous floxed c-Myb (*Myb*^F/+^, *Mx1-Cre*), showed obvious increase of PD-L1 expression in CD11b^+^Gr-1^-^ BM cells ([Figure 6C,D,E](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1A,B,C](#fig6s1){ref-type="fig"}), despite of significant decrease of BM whole leukocytes due to *Myb*-reduction induced cell apoptosis. To avoid excessive apoptosis and test if the down-regulation of *Myb* was necessary and sufficient to cause accumulation of IMLECs, we transplanted BM cells from either *Myb^F/F^, Rag2^-/-^* or *Myb^F/F^, Rag2^-/-^, CreER* mice to CD45.1^+^ recipients, which then received tamoxifen to achieve deletion of *Myb* specifically in donor-derived hematopoietic cells after their full reconstitution ([Figure 6F](#fig6){ref-type="fig"}). Consistent with essential role for c-Myb in hematopoiesis, surviving leukocytes appeared heterozygous for *Myb* deletion ([Figure 6G](#fig6){ref-type="fig"}). As early as 1 week after the first injection of tamoxifen, a significant decrease in CD11b^+^ Gr-1^+^ granulocytes and an increase in CD11b^+^ Gr-1^-^ PD-L1^+^ IMLECs were observed in *Myb* cKO BM ([Figure 6H](#fig6){ref-type="fig"}). Moreover, the provision of heterologous c-Myb significantly diminished the generation of IMLECs from Raptor-deficient LSK cells in our in vitro OP9 co-culturing experiments ([Figure 6---figure supplement 1D,E,F,G](#fig6s1){ref-type="fig"}). Therefore, down-regulation of *Myb* is necessary for production of IMLECs.

![Inactivation of *Myb* is an underlying cause for accumulation of IMLEC.\
(**A**) Reduction of *Myb* mRNA in the *Rptor*-deficient HSPCs. BM LSK and CMP populations were FACS-sorted from Ctrl and cKO mice at 1--3 weeks after pIpC treatment. Quantitation of *Myb* mRNA was performed by qPCR. n = 5 for Ctrl-LSK; n = 4 for cKO-LSK (left). n = 4 for Ctrl-CMP; n = 3 for cKO-CMP (right). (**B**) Detection of c-Myb protein by intracellular staining. Data represent one of three independent experiments with similar results. (**C--E**) Deletion of c-Myb in mice with homozygous floxed *Myb* resulted in enhanced generation of IMLECs. (**C**) Schematic of experimental design. Sex-matched 6--8 weeks old c-Myb Ctrl (*Myb ^F/F^*) and cKO (*Myb ^F/F^, Mx1-Cre*) mice were treated with pIpC for seven times. The phenotypes were analyzed on day seven after the complement of pIpC treatment. Inducible deletion of c-Myb showed obvious increase of PD-L1 expression on CD11b^+^Gr-1^-^ BM cells (**D**) and production of IMLECs (**E**). n = 3 for c-Myb Ctrl mice; n = 3 for c-Myb cKO mice. (**F--H**) Deletion of *Myb* enhances generation of IMLEC. (**F**) Diagram of experimental design. Whole BM cells (2 × 10^6^/mice) of given genotypes were used for transplantation. Once the chimera mice were established, deletion of *Myb* was induced by five daily injection of tamoxifen. (**G**) Detection of *Myb* deletion in the whole BM cells after tamoxifen treatments. Data are representative of two independent experiments. (**H**) Generation of IMLEC is promoted by inactivation of *Myb.* BM cells were harvested at 7 days after first tamoxifen treatment and analyzed for IMLECs based on surface markers CD11b, Gr-1 and PD-L1 within the donor-derived CD45.2^+^ BM cells. Data shown represent one of three experiments using either first or second generation of BM chimeras. (**I**) *Rptor* deletion broadly increases miRNAs targeting *Myb*. Lin^-^ c-Kit^+^ HSPCs were isolated from Raptor Ctrl and cKO mice at 10 days after pIpC treatment. miRNA levels were measured by miRNA microarray. The y-axis shows the log~2~ ratio of signal, while the x-axis shows the -log~10~P value. The doted boxes show the numbers of significantly (p\<0.05) up-regulated (fold change \>2) or down-regulated (fold change \<0.5) miRNAs among 50 miRNAs with mirSVR score \<−1.0. Each dot represents the mean value of a unique miRNA from three independent samples.](elife-32497-fig6){#fig6}

We recently reported that deletion of *Rptor* caused up-regulation of miRNA biogenesis in HSPCs ([@bib87]). We searched our miRNA microarray database and mirSVR score database ([@bib6]) for potential impact of miRNAs in down-regulation of *Myb* expression. Using the stringent criteria of mirSVR score \<−1.0, we identified 50 miRNAs that presented in the HSPCs ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Among them, 13 miRNAs showed \>2.0 folds up-regulation in the *Rptor*-deficient HSPCs (p\<0.05), while none showed statistically significant down-regulation ([Figure 6I](#fig6){ref-type="fig"}). Significant up-regulation of miR-150 (1.4 folds increase, p=0.05), which was previously demonstrated to inhibit *Myb* expression ([@bib46]; [@bib86]), was also observed. Up-regulation of *Myb-*targeting miRNAs provides a plausible mechanism for down-regulation of *Myb* by *Rptor* deletion. However, the broad spectrum of the up-regulated miRNAs suggests that it is unlikely that a single miRNA is responsible for the overall reduction of *Myb* expression.

Expansion of IMLECs associated with lethal inflammatory response to TLR ligands {#s2-5}
-------------------------------------------------------------------------------

RNA-seq data indicated that IMLECs broadly up-regulate pattern recognition receptors (PRRs) genes. TLRs, the first family of PRRs identified, were broadly over-expressed in cKO IMLECs as determined by RNA-seq ([Figure 7A](#fig7){ref-type="fig"}). RT-PCR confirmed that IMLECs from both cKO and WT mice over-expressed essentially all TLRs tested, particularly *Tlr2*, *Tlr3*, *Tlr4*, *Tlr6*, *Tlr7*, *Tlr8* and *Tlr9* ([Figure 7B](#fig7){ref-type="fig"}). In addition to TLRs, expression of other PRRs, including NLRs, ALRs and RLRs, was also broadly elevated ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). When the BM from Ctrl and *Rptor^-/-^* mice were compared for their responses to TLRs agonists, including synthetic *tripalmitoylated lipopeptide* Pam3CysSerLys4 (Pam3CSK4, TLR1/2 agonist), heat-killed *Listeria monocytogenes* (HKLM, TLR2 agonist), synthetic analog of double-stranded RNA poly I:C (pIpC, TLR3 agonist), lipopolysaccharide (LPS, TLR4 agonist), flagellin from *Salmonella typhimurium* (FLA-ST, TLR5 agonist), synthetic lipoprotein derived from *Mycoplasma salivarium* (FSL-1, TLR2/6 agonist), single-stranded RNA Double-Right complexed with LyoVec (ssRNA-DR, TLR7 agonist) and synthetic oligonucleotides containing unmethylated CpG dinucleotides (ODN1826, TLR9 agonist), it is clear that *Rptor^-/-^* BM increased production of TNF-α ([Figure 7C](#fig7){ref-type="fig"}) and MCP-1 ([Figure 7D](#fig7){ref-type="fig"}) in response to all TLR ligands tested. To determine the cellular basis for the enhanced cytokine production, we used intracellular and cell surface staining to identify cells that produced the inflammatory cytokines. As shown in [Figure 7E](#fig7){ref-type="fig"}, IMLECs from both WT and *Rptor* cKO BM were potent producers of TNF-α when stimulated by LPS.

![IMLECs broadly express PPRs and produce large amounts of inflammatory cytokines upon stimulation by various TLR ligands.\
(**A**) Heat map showing the relative transcript levels of TLRs among the indicated populations. (**B**) Both WT and Raptor-cKO IMLECs have greatly elevated expression of multiple TLRs genes in comparison to Ctrl BM. q-PCR was performed to determine transcript levels of *Tlr1-9* genes. After normalizing for cDNA input based on *Hprt* mRNA in each sample, the *Tlr1-9* levels in the FACS-sorted cKO CD11b^+^ Gr-1^-^ BM IMLEC were compared with Ctrl BM (artificially defined as 1.0). n = 3 for Ctrl WBM; n = 5 for cKO- IMLEC; n = 5 for WT-IMLEC. Similar results were obtained using mice sacrificed at 2 weeks \~2 months after pIpC treatment. (**C, D**) In responses to various TLR ligands, *Rptor* cKO BM cells produced greatly elevated amounts of TNF-α (**C**) and MCP-1 (**D**) than the Ctrl BM. Data shown are from one experiment involving three repeats per group and have been reproduced in five independent experiments. (**E**) Lin^-^ (B220^-^CD3^-^Ter119^-^Gr-1^-^NK1.1^-^F4/80^-^CD115^-^) CD11b^+^ PD-L1^+^ IMLECs from both cKO and WT BM were robust TNF-α producers after stimulation with LPS. BM cells (1 × 10^7^ cells / well) were stimulated with LPS (1 μg/ml) for 16 hr with the presence of Golgi blocker in the last 4 hr. Data shown are representative profiles from one experiment and have been reproduced in three independent experiments.](elife-32497-fig7){#fig7}

Consistent with exacerbated responses to TLR ligands in BM cells, deletion of *Rptor* in cKO mice resulted in massive increase in inflammatory cytokines in serum ([Figure 8A](#fig8){ref-type="fig"}). Approximately 40% of cKO mice died within 2 months after 7 pIpC treatments ([Figure 8B](#fig8){ref-type="fig"}). Histological analyses revealed extensive inflammation in the liver with associated tissue injuries ([Figure 8C](#fig8){ref-type="fig"}). A substantial proportion of the leukocytes in the liver of cKO mice were IMLECs, as demonstrated by cell surface markers CD11b^+^ Gr-1^-^ PD-L1^+^ F4/80^low/-^ ([Figure 8D,E](#fig8){ref-type="fig"}). To test if the mice with expanded IMLECs were more sensitive to endotoxin, we challenged the Ctrl and cKO mice with low doses of LPS (5 mg/kg body weight). While all Ctrl mice survived the LPS challenge, all cKO mice succumbed within 36 hr ([Figure 8F](#fig8){ref-type="fig"}). The dramatically increased mortality due to endotoxic shock was associated with remarkably elevated levels of inflammatory cytokines. As shown in [Figure 8G](#fig8){ref-type="fig"} and [Figure 8H](#fig8){ref-type="fig"}, a more than 500-fold increase in TNF-α and an approximately 10-fold increase of MCP-1 were detected in the serum of cKO mice at 6 hr after LPS injection. It has been demonstrated that acetaminophen-triggered liver necrosis induces HMGB-1-mediated inflammatory responses to danger-associated molecular patterns (DAMPs) ([@bib10]; [@bib68]). As shown in [Figure 8I](#fig8){ref-type="fig"} and [Figure 8J](#fig8){ref-type="fig"}, cKO mice mounted a significantly elevated inflammation to challenge by low doses of acetaminophen. Therefore, amplification of IMLEC also leads to elevated response to tissue injuries.

![Rptor cKO mice are hyper sensitive to challenges by TLR ligands.\
(**A**) High blood levels of inflammatory cytokines in cKO mice that have received 7 pIpC treatments. Serum samples collected at 7 days after the last pIpC treatment were tested for levels of IL-12p70, TNF-α, IFN-γ, MCP-1, IL-10 and IL-6. Dot plots depict cytokine levels in individual cKO (red dots) or Ctrl (blue dots) mice, and line drawings depict means and SD. n = 12 for Ctrl mice and n = 11 for cKO mice. (**B**) High proportions of *Rptor* cKO mice that received 7 pIpC injections died within 7 weeks after first pIpC treatment. Data shown are Kaplan-Meier survival curve, and the statistical significance is determined by log-rank test. n = 32 for Ctrl mice and n = 31 for cKO mice. (**C**) Representative H and E staining of liver sections from *Rptor* Ctrl and cKO mice at 2 weeks post pIpC treatment. Scale bars represent 200 μm (10X) and 50 μm (40X), respectively. (**D, E**) Massive accumulation of IMLEC in cKO liver. (**D**) Accumulation of CD11b^+^ Gr-1^-^ cells in the cKO liver. (**E**) CD11b^+^ Gr-1^-^ cells in cKO livers demonstrated IMLEC surface markers, including PD-L1^high^ and F4/80^low/-^. Gray lines indicate the staining for isotype control antibodies. Results are representative of at least five independent analyses. (**F--H**) cKO mice are vulnerable to low doses of LPS challenges. At 2--3 months after pIpC treatments, cKO and Ctrl mice were challenged with 5 mg/kg body weight of LPS and observed survival. (**F**) Kaplan- Meier survival analysis. Data are pooled from three independent experiments. n = 14 for Ctrl mice; n = 11 for cKO mice. Inflammatory cytokines TNF-α (**G**) and MCP-1 (**H**) levels from mice serum before (0 h) and at 6 hr after (6 h) LPS injection are shown. n = 10 for Ctrl mice; n = 9 for cKO mice. Note greater than 500-fold increase in plasma TNF-α levels. (**I, J**) cKO mice mounted enhanced inflammatory response to acetaminophen-triggered liver necrosis. Serum TNF-α (**I**) and MCP-1(**J**) levels at 6 hr upon acetaminophen (3.2 mg/mouse) treatment are shown. n = 4 for Ctrl mice; n = 6 for cKO mice. Mann-Whitney test was used for statistics analysis, and lines indicate Mean ±SD. Similar trends were observed in another independent experiment.](elife-32497-fig8){#fig8}

Since *Mx1-Cre* was broadly activated after pIpC treatment, it is less certain whether the increased sensitivity of the cKO mice to TLR ligands is due to immunological abnormality. To address this issue, we produced chimeric mice in which pIpC induces deletion of the targeted gene exclusively in hematopoietic cells by transplanting *Rptor^F/F^, Mx1-Cre* (CD45.2^+^) BM cells into lethally irradiated CD45.1^+^ recipients. After hematopoietic reconstitution, the recipients were treated with 3 doses of pIpC to induce deletion of *Rptor* exclusively in the hematopoietic cells. After 10 days of pause, the Ctrl and cKO chimera mice were challenged with new pIpC injection and monitored for survival ([Figure 9A](#fig9){ref-type="fig"}). As shown in [Figure 9B](#fig9){ref-type="fig"}, while a large portion of the cKO chimera mice died progressively starting within a week of the second round of pIpC treatment, all Ctrl chimera mice survived the observation period of more than 45 days. Massive leukocytes infiltration was observed in the liver of cKO chimeric mice ([Figure 9C](#fig9){ref-type="fig"}). Cell surface phenotyping of the donor-type leukocytes in BM ([Figure 9D](#fig9){ref-type="fig"}), spleen ([Figure 9E](#fig9){ref-type="fig"}) and liver ([Figure 9F](#fig9){ref-type="fig"}) revealed accumulation of CD11b^+^ Gr-1^-^ PD-L1^+^ F4/80^low/-^ IMLECs. Collectively, the data in [Figure 8](#fig8){ref-type="fig"} and [Figure 9](#fig9){ref-type="fig"} demonstrate that over-expansion of IMLECs, as a result of *Rptor* deletion, renders the host highly vulnerable to TLR ligands.

![*Rptor* deletion in hematopoietic cells greatly increases vulnerability of mice to pIpC.\
(**A**) Diagram of experimental design. WT CD45.1^+^ recipient mice were irradiated and transplanted with 5 × 10^6^ BM cells from *Rptor^F/F^* and *Rptor^F/F^, Mx1-Cre* BM. After the fully reconstitution, recipients were treated with pIpC three times every other day to induce gene deletion in chimera mice with cKO BM. 10 days after the last injection of pIpC, recipients were challenged with another pIpC injection and the survival of mice were followed for four more weeks. Arrows denote the injections of pIpC at indicated time points. (**B**) Kaplan-Meier survival analysis after pIpC treatments. n = 12 for Ctrl chimera mice; n = 15 for cKO chimera mice. (**C**) Histological analysis of liver sections after H&E staining. Note extensive inflammation and liver damage in cKO chimera mice. Scale bars represent 200 μm (10X), 100 μm (20X) and 50 μm (40X). (**D--F**) Identification of IMLEC in BM (**D**), spleen (**E**) and livers (**F**) by flow cytometry. Mice were euthanized 45 days after the first pIpC injection. The distinct CD11b^+^ Gr-1^-^ PD-L1^+^ F4/80^low/-^ IMLECs greatly enriched in BM, spleen and liver of recipients of *Rptor* cKO BM. FACS profiles shown represent one of five independent experiments.](elife-32497-fig9){#fig9}

Discussion {#s3}
==========

We have characterized a leukocyte population, which we called IMLECs, that has a strong innate effector function but with features of both myeloid and lymphoid cells. Furthermore, our data reveal an unexpected function of mTORC1 in suppressing IMLEC expansion. The high vulnerability to TLR ligands after IMLEC expansion highlights a new consequence of defective hematopoiesis and a new mechanism of immune tolerance.

Two groups have previous reported that inactivation of mTORC1 by deletion of *Rptor* leads to massive accumulation of CD11b^+^Gr-1^-^ cells in the BM ([@bib30]; [@bib34]). Similar results were obtained in mice with *Mtor* deletion in the hematopoietic cells ([@bib26]). We have demonstrated here that despite expression of a myeloid cell marker CD11b, the CD11b^+^Gr-1^-^ BM cells have lymphoid morphology. The active production of sterile transcripts at Ig loci suggests that these cells have partially committed to the B-cell lineage, while lack of VDJ rearrangement and cell surface B cell markers suggests that the differentiation toward the B cell lineage is limited. Importantly, this cell population expresses high levels of PD-L1 but does not express markers for other lymphoid cells including T cells (CD3) and NK cells (NK1.1) as well as for myeloid cells including F4/80, Gr-1 and CD115. Expression of CD11b also distinguishes IMLECs from ILCs ([@bib82]), which are CD11b^-^. PCA analysis demonstrated that IMLECs are distinct from but close to B cells and macrophages in gene expression profiles. While at much lower frequencies, cells with the same phenotypes and functional properties were also identified in normal BM, peripheral lymphoid and non-lymphoid organs.

It is of interest to note that the hallmark of IMLECs is the high expression of cell surface PD-L1. First identified as B7-H1 ([@bib17]), PD-L1 has been shown to be involved in tumor evasion of T cell immunity, both by inducing exhaustion of effector T cells and by shielding tumor cells from effector T cells ([@bib28]; [@bib3]). With the induction by cytokines such as IFN-γ and hypoxic tumor microenvironment, PD-L1 has been found on both tumor cells and host inflammatory cells such as myeloid derived DCs ([@bib14]; [@bib18]), tumor-infiltrating myeloid derived suppressor cells ([@bib58]). Recent studies have demonstrated that PD-L1 is an important biomarker and therapeutic target in cancer immunotherapy ([@bib24]; [@bib7]). Since IMLECs constitutively express high levels of PD-L1, it will be of interest to investigate their function in cancer immunity. It's worth noting that IMLECs of Raptor-deficient BM have an overall higher expression of PD-L1 than that of Raptor-sufficient BM, perhaps this reflects the indirect consequence of reduced mTORC1-mediated translation of PD-L1 negative regulators.

Since the IMLEC population expanded at the expense of granulocytes in the BM, we tested if IMLECs were derived by trans-differentiation of the granulocytes. Our genetic analyses demonstrated that inactivation of mTORC1 in the granulocytes, using *Lyz2-Cre*, failed to produce this subset, suggesting that loss of mTORC1 in granulocytes does not cause their trans-differentiation into IMLECs. Furthermore, since inactivation of mTORC1 in CD11b^+^Gr-1^+^ granulocytes did not affect their abundance in BM, loss of granulocytes in the mice with broad deletion of *Rptor* in all hematopoietic cells was not due to a cell-intrinsic requirement for mTORC1 in survival of granulocytes. Since IMLECs generally do not undergo active proliferation and are prone to apoptosis, their massive accumulation is most likely due to continuous production rather than self-renewal. Indeed, while LSKs and CMPs differentiate into IMLECs both in vitro and in vivo, IMLECs are not able to propagate in vivo (data not shown). Since *Lyz2-Cre* mediated *Rptor* deletion does not result in accumulation of IMLECs, it is obvious that IMLEC differentiation pathway is initiated before *Lyz2-Cre* expression which also occurs in some CMPs, and not all CMPs can give rise to IMLEC. On the other hand, since CLPs give rise to IMLEC in vitro, the possibility that other progenitor cells may give rise to IMLECs has not been ruled out.

Since heterozygous mutation of *Myb* causes an increase of CD11b^+^Gr-1^low/-^ cells in BM ([@bib23]), we tested if conditional deletion of *Myb* is sufficient to cause accumulation of IMLEC. Our data demonstrate that cell-intrinsic reduction of *Myb* in BM resulted in accumulation of CD11b^+^ Gr-1^-^ PD-L1^+^ IMLECs. It is of interest to note that mice with inactivation of *Rptor* share many hematopoietic phenotypes with mice harboring targeted disruption of *Myb*, such as an increase in HSPCs ([@bib67]) and defective B-lymphopoiesis ([@bib19]; [@bib80]; [@bib25]). Moreover, consistent with the proposed roles of c-Myb in regulating precise hematopoietic commitments, CMPs with deletion of either *Rptor* or *Myb* favored differentiation to CD11b^+^ Gr-1^-^ cells ([@bib44]). Since our data show that the majority of the CD11b^+^Gr-1^-^ cells generated from CMPs are IMLECs, these data support the notion that IMLEC accumulation in *Rptor* cKO BM is caused by reduced *Myb* expression in CMPs.

While the mechanism by which mTORC1 down-regulates *Myb* remains to be fully elucidated, we have found a general up-regulation of putative miRNAs targeting *Myb* in HSPCs after *Rptor* deletion. Our data suggest that mTORC1 inactivation in HSPCs expands IMLECs by down-regulation of *Myb*, perhaps through increased miRNA biogenesis.

Previous studies by us and others have demonstrated a critical role for regulated mTOR signaling in hematopoiesis ([@bib88]; [@bib89]; [@bib9]). Thus, while mTOR activation by deletion of *Tsc1* complex expands the numbers of hematopoietic stem cells, it causes reduced hematopoietic stem cell function but induced leukemic stem cells in conjunction with *Pten* deletion. This is consistent with the generally accepted association between defective differentiation and leukemiogenesis, which forms the foundation for treatment of leukemia through induction of differentiation ([@bib60]). The expansion of IMLECs caused by mTORC1 inactivation did not lead to leukemiogenesis as IMLECs are non-dividing cells that undergo a high rate of apoptosis. Instead, our data demonstrate a new consequence of defective differentiation, namely generation of a new population of cells with distinct effector function, as discussed below.

Our RNA-seq data suggest that IMLECs broadly over-express pattern recognition receptors for innate immunity. Corresponding to a broad, although not universal TLR elevation, IMLECs mount drastically exacerbated responses to all TLR ligands tested in vitro. Intracellular cytokine staining revealed that both normal and *Rptor*-cKO IMLECs were among the most active producers of inflammatory cytokines. Surprisingly, although *Rptor^-/-^* BM cells have normal TLR5 levels, they produce 10--20 folds more inflammatory cytokines, such as TNF-α and MCP-1 in response to TLR5 ligand. It is therefore likely that beyond TLRs, IMLECs have acquired other features that enhance their response to TLR ligands.

Apart from BM, expanded IMLECs are broadly distributed in lymphoid and non-lymphoid organs such as lung and liver. Our data demonstrate that an increase in IMLEC numbers makes the host highly vulnerable to TLR ligands such as LPS and polyI:C, as indicated by rapid demise of mice following pIpC and low doses of LPS injections. Since necrosis of normal tissues leads to release of endogenous TLR ligands, such as HMGB1 ([@bib68]) and HSP70 ([@bib55]), and since unregulated host response to HMGB1 leads to fatal inflammation ([@bib10]), it is conceivable that expansion of IMLECs may also make the host more vulnerable to tissue injury- induced inflammation. This is evidenced by elevated inflammation in acetaminophen-triggered liver necrosis model.

The severe pathological consequences may explain the paradoxical functions of mTOR in regulation of inflammation. While mTOR signaling is known to be activated by inflammatory cytokines ([@bib11]) and rapamycin has been shown to inhibit production of inflammatory cytokines ([@bib1]), perhaps through its inhibition of mTOR-mediated NFκB activation ([@bib43]), rapamycin has been shown to induce inflammation in a small number of transplantation patients ([@bib15]; [@bib79]; [@bib16]). Likewise, we have observed that rapamycin increases production of inflammatory cytokines in autoimmune Scurfy mice and in mice treated with high doses of endotoxin ([@bib11]). It would be of great interest to determine if rapamycin can expand IMLECs in transplantation patients and in mice that either receive high doses of endotoxin or are genetically predisposed to autoimmune disease. It is also reported that persistent mTORC1 inhibition can result in elevated inflammation, activation of STAT3 and enhanced hepatocellular carcinoma development ([@bib81]). Our findings focused on characterizing IMLECs and inflammation support the provocative findings of this report, and might provide alternative and complementary explanations. However, despite an extensive effort, we have failed to induce IMLECs by mTOR kinase inhibitor Torin2 or rapamycin in WT mice (data not shown). Therefore, under normal circumstances, pharmaceutical inhibition of mTORC1 alone cannot achieve comparable levels of inflammation as those achieved by genetic inactivation of either *Mtor* or *Rptor*. Additional conditions must be met for mTOR inhibitors to cause inflammation. While these unknown barriers have ensured safety of mTOR inhibitors in most circumstances, their breakdown may explain paradoxical induction of inflammation by rapamycin.

The concept of immune tolerance has traditionally been reserved for adaptive immunity to avoid autoimmune diseases. A multitude of mechanisms, including clonal deletion ([@bib71]; [@bib39]; [@bib35]), clonal anergy ([@bib59]; [@bib70]) and dominant regulatory T cells ([@bib66]), have been described to reduce self-reactive T and B cell clone sizes to avoid autoimmune diseases. On the other hand, innate immunity is known to be regulated at levels of cellular activation ([@bib41]) and cellular recruitment ([@bib74]). However, we and others have reported that innate immune effectors, especially NK cells, have features of adaptive immunity as their immune protective function against cancer and viruses is amplified through increased population sizes ([@bib22]; [@bib76]). However, a regulatory mechanism to control innate effector population size for the sake of preventing self-destruction has not been described. Our discovery of a developmentally regulated mechanism to control the population size of IMLECs to avoid unwanted self-destruction, as described herein, reveals a parallel between adaptive and innate immunity to avoid potentially life-threatening inflammation and tissue damage. It is therefore of interest to consider the concept of immune tolerance in the area of innate immunity.

An important consideration is whether IMLEC is a normal population of hematopoietic cells or a population that arises after pathogenic mutations. While we have identified cells of similar phenotypes and functional properties in normal mice, they are extremely rare and thus have no obvious physiological functions unless they are substantially expanded. We have demonstrated that these cells do not undergo proliferation and are prone to apoptosis, and that their expansion depends on abnormal hematopoiesis. Therefore, the pathological consequence observed herein is only known to manifest itself if the mTORC1-Myb pathway is genetically inactivated, resulting in disruption of normal hematopoiesis. Further studies are needed to identify conditions that can lead to accumulation of IMLEC short of these known mutations.

In summary, our data demonstrate that inactivation of mTORC1 in hematopoietic stem/progenitor cells leads to generation of IMLECs, a new cell population that shares features with myeloid and lymphoid lineages. The greater than 500-fold increase in population size of IMLECs in mTORC1- or *Myb*-defective BM highlights the critical role for mTORC1 and c-Myb in repressing the development of sufficient number of IMLECs to cause serious inflammation and tissue damage. Our study reveals a new consequence of defective hematopoiesis and may help to extend the concept of immune tolerance to innate immunity.

Materials and methods {#s4}
=====================

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type (species) or resource                   Designation                  Source or reference      Identifiers                                                              Additional information
  ---------------------------------------------------- ---------------------------- ------------------------ ------------------------------------------------------------------------ ------------------------
  strain, strain background (*Mus musculus,C57BL/6*)   *Rptor^F/F^*                 PMID: 19046572                                                                                    

  strain, strain background (*Mus musculus,C57BL/6*)   *Myb^F/F^;*\                 PMID: 15195090;\                                                                                  
                                                       *Myb^F/F^,Rag2^-/-^,CreER*   PMID: 16169500                                                                                    

  strain, strain background (*Mus musculus,C57BL/6*)   *Mx1-Cre*                    The Jackson Laboratory   Stock No: 003556;\                                                       
                                                                                                             RRID:[IMSR_JAX:003556](https://scicrunch.org/resolver/IMSR_JAX:003556)   

  strain, strain background (*Mus musculus,C57BL/6*)   *CreER*                      The Jackson Laboratory   Stock No: 007001;\                                                       
                                                                                                             RRID:[IMSR_JAX:007001](https://scicrunch.org/resolver/IMSR_JAX:007001)   

  strain, strain background (*Mus musculus,C57BL/6*)   *Lyz2-Cre*                   The Jackson Laboratory   Stock No: 004781;\                                                       
                                                                                                             RRID:[IMSR_JAX:004781](https://scicrunch.org/resolver/IMSR_JAX:004781)   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice and induction of gene deletion {#s4-1}
-----------------------------------

*Rptor ^F/F^* mice ([@bib5]) were crossed to the C57BL/6 background for more than 10 generations. *Myb ^F/F^* and *Myb ^F/F^, Rag2^-/-^*, *CreER* mice were reported previously ([@bib19]; [@bib80]; [@bib4]). The interferon-inducible *Mx1-Cre* transgenic mice (RRID:[IMSR_JAX:003556](https://scicrunch.org/resolver/IMSR_JAX:003556)) ([@bib42]), tamoxifen-inducible *Cre-ER^T2^* transgenic mice (RRID:[IMSR_JAX:007001](https://scicrunch.org/resolver/IMSR_JAX:007001)) ([@bib31]) and *Lyz2-Cre* knock-in mice (RRID:[IMSR_JAX:004781](https://scicrunch.org/resolver/IMSR_JAX:004781)) ([@bib12]) with C57BL/6 background were purchased from the Jackson Laboratory. *Rptor ^F/F^* mice were crossed with *Mx1-Cre* mice, *Lyz2-Cre* mice or *CreER* mice to produce *Rptor ^F/F^, Mx1-Cre* (cKO) mice, *Rptor ^F/F^*, *Lyz2-Cre^+/+^* mice or *Rptor*^F/F^, *CreER* mice, respectively. *Myb ^F/F^* mice were crossed with *Mx1-Cre* mice to generate *Myb*^F/F^ (Ctrl) and *Myb*^F/F^, *Mx1-Cre* (cKO) mice. Offspring of these mice were genotyped by PCR-based assays with genomic DNA from mouse tail snips. Mice were cared for in the Unit of Laboratory Animal Medicine (ULAM) at the University of Michigan, where these studies were initiated, or Research Animal Facility (RAF) of Children's National Medical Center, where the studies were completed. All procedures involving experimental animals were approved by the University Committee on the Use and Care of Animals (UCUCA) at the University of Michigan or Children's National Medical Center.

Raptor Ctrl and cKO mice used in each experiment were sex-matched littermates. Mice were given 2 mg/kg body weight of pIpC (GE Healthcare Life Sciences) or 400 µg pIpC (Sigma-Aldrich) every other day for consecutive 3 to 7 times as specified by intra-peritoneal (i.p.) injection to induce Cre expression as in previous study ([@bib78]). Deletion of target genes were confirmed as previously described ([@bib5]; [@bib4]). Wild type C57BL/6 (CD45.2) mice and congenic C57BL/6 (CD45.1) mice were purchased from the Charles River Laboratories. Tamoxifen (Sigma-Aldrich) was dissolved in corn oil (Sigma-Aldrich) to 20 mg/ml and injected i.p. at 150 mg/kg/day for five consecutive days.

Histology, cytology and complete blood cell count {#s4-2}
-------------------------------------------------

Ctrl and cKO mice were euthanized by CO~2~ inhalation on day 30 of last pIpC treatment. For histology, tissues were fixed in 10% neutral buffered formalin for 24--48 hr and the sternums were then decalcified in Immunocal (formic acid-based decalcifier, Decal, Tallman, NY) for 24 hr. Tissues were trimmed and cassetted and processed to wax on an automated processor using standard methods. Sections were cut at 5 μm thickness and hematoxylin and eosin-stained slides prepared on an automated stainer. For cytology, BM was collected from the femoral marrow cavity with a fine diameter paintbrush dipped in sterile PBS with 5% fetal bovine serum and cytology smears were prepared by gently brushing the collected cells in parallel lines on a glass slide. Cytology slides of BM smear and cytospins of FACS-sorted BM cells were stained using a Romanowsky-based stain (Diff-Quik, Hema 3 Manual staining system, Fisher Scientific).

Histological and cytological parameters were evaluated using an Olympus BX45 light microscope at total magnifications ranging from 40 X to 100 X (oil). Histological alterations were descriptively identified. Cytological alterations were descriptively identified and quantitative BM differential counts were made using a manual differential counter and standard criteria for cell identification. Images were taken using a 12.5 megapixel microscope-mounted Olympus DP72 digital camera and accompanying software (Olympus). Complete blood cell count was performed using the Hemavet 950 Hematology System (Drew Scientific Inc.) by the Animal Diagnostic Laboratory of ULAM Pathology Cores for Animal Research in the University of Michigan.

Cells preparation and bleeding {#s4-3}
------------------------------

BM cells were flushed out from the long bones (tibiae and femurs) by a 25-gauge needle with staining buffer (1XHanks Balanced Saline Solution without calcium or magnesium, supplemented with 2% heat-inactivated fetal bovine serum). Single cell suspensions of spleen, thymus, lung and lymph nodes were generated by gently squashing with frosted slides in a small volume of staining buffer. Cells from mouse peritoneal cavity were harvested as described before ([@bib64]). For isolation of mouse liver mononuclear cells, liver fragments were pressed through 70 μm round cell strainer (Becton Dickinson). Single-cell suspensions in a 35% Percoll solution (GE Healthcare) were centrifuged for 20 min at 800 g with brake off at room temperature. Pellet was collected and washed with staining buffer. Peripheral blood was collected by retro-orbital bleeding with heparinized capillary tubes or by submandibular bleeding with a lancet.

Flow cytometry {#s4-4}
--------------

For surface staining, cells were stained with the indicated antibodies (Abs) in staining buffer for 20 min at 4°C. In the characterization of surface markers for CD11b^+^ Gr-1^-^ cells, Fcγ receptors were pre-blocked by incubating cells with culture medium from hybridoma 2.4G2 ([@bib40]) for 20 min at 4°C. For intracellular staining, cells were first stained with the indicated surface markers Abs and then fixed with Cytofix/Cytoperm buffer (BD Biosciences) for 1--2 hr at 4°C, followed by incubation with Cytoperm Plus buffer (BD Biosciences) for 15 min at room temperature (R.T.). After refixing for 15 min at R.T., cells were incubated with antibodies or isotype controls for 20 min (anti-TNF/IgG, anti-Ki-67Abs) or overnight (anti-c-Myb/IgG Abs) and further stained with the secondary Ab if necessary. BrdU labeling experiments were performed per the manufacture's instruction (BD Biosciences), as previously reported ([@bib9]; [@bib78]). Apoptosis assays by 7-AAD and Annexin V (BD Biosciences) were according to manufacturer's instructions. All FACS analyses were performed on a BD LSR II or a Canto II Flow Cytometer, and data were analyzed with FlowJo software (Tree Star, Inc.). The enrichment of Lin^-^ BM cells was performed using MACS beads from mouse Lineage Cell Depletion Kit (Miltenyi Biotec). CD11b^+^ Gr-1^-^ BM cells from *Rptor ^F/F^, Mx1-Cre* mice, Lin^-^ CD11b^+^ PD-L1^+^ IMLECs / LSK/CLP/ CMP populations from Raptor Ctrl/cKO or WT mice, CD11b^+^ Gr-1^+^ / CD11b^-^ Gr-1^-^ BM populations from *Rptor ^F/F^, Lyz2-Cre^+/+^* mice, CD11b^high^ Gr-1^-^ F4/80^+^ peritoneal macrophages were sorted using FACSAria II or Influx cell sorter (BD Biosciences). The detailed information on Abs used in this study is in [Supplementary file 3](#supp3){ref-type="supplementary-material"}.

BM cells transplantation {#s4-5}
------------------------

C57BL/6 Ly5.2 (CD45.1^+^) recipient mice at the age of 6--12 weeks old were lethally irradiated for total 900--1,100 rads with a Cs-137 γ-ray source or a RS 2000 X-ray irradiator (Rad Source Technologies, Inc.). Indicated donor BM cells (whole BM or FACS-sorted BM cells) were transplanted into recipients through the mice tail by intra-venous (i.v.) injection within 24 hr after irradiation ([@bib78]). At different time points post-transplantation, peripheral blood from the recipient mice was analyzed by flow cytometry to test the reconstitutions.

Conventional PCR and quantitative PCR {#s4-6}
-------------------------------------

Genomic DNA was isolated from BM cells by DNeasy Blood and Tissue Kit (Qiagen) as per manufacturer's instructions. Total RNA was isolated using TRIzol (Invitrogen) or ReliaPrep RNA Cell Miniprep System (Promega). Reverse transcription was carried out using random hemaxmer primers and SuperScript II Reverse Transcriptase (Invitrogen). Conventional PCR was performed using GoTaq Green Master Mix (Promega). Quantitative PCR (q-PCR) was performed by the 7500 real-time PCR system using Power SYBR Green Master Mixture (Applied Biosystems). Fold changes were calculated according to the ΔΔCT method ([@bib51]). The primers used for conventional PCR and q-PCR are listed in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

Ig gene rearrangement test by V(D)J analysis {#s4-7}
--------------------------------------------

Immunoglobulin (Ig) gene recombination was determined using genomic DNA as previously described ([@bib65]). For Heavy chain, a semi-nested PCR strategy was employed to amplify the framework regions of VH to specific sites of JH. First round amplification of 25 cycles was performed with primers FR/JH1 (70°C annealing/20 s extension). Second round amplification of 35 cycles was with primers FR/JH2 (65°C annealing/30 s extension). Light chain (I*gk* and *Igl*) recombination was tested by primers V~κ~/J~κ~5 and V~λ~1/J~λ~1,3 following previous report ([@bib13]). Sequences of primers used are listed in [Supplementary file 4](#supp4){ref-type="supplementary-material"}.

OP9 cell co-culturing with HSPCs {#s4-8}
--------------------------------

OP9 stromal cell line (ATCC Cat\# CRL-2749, RRID:[CVCL_4398](https://scicrunch.org/resolver/CVCL_4398)) was purchased from American Type Culture Collection (ATCC, Manassas, USA). No cell lines used in this study were listed in the database of cross-contaminated or misidentified cell lines suggested by International Cell Line Authentication Committee (ICLAC). All cell lines from ATCC were authenticated by the STR profiling method and tested as mycoplasma contamination free by ATCC. OP9 cells were maintained in α-MEM medium (Life Technologies) supplemented with 20% heat-inactivated fetal bovine serum (Hyclone), 100 units/ml of penicillin and 100 µg/ml of streptomycin (Gibco). The 6-well and 12-well flat-bottomed plates were pre-coated with OP9 cells at approximate 100% confluence after overnight growth. Subsequently 2 × 10^3^ LSK (Lin^-^ c-Kit^+^ Sca-1^+^) or 5 × 10^4^ CMP (Lin^-^ c-Kit^+^ Sca-1^-^ CD34^Medium^CD16/32^Medium^) cells or 5 × 10^4^ CLP (Lin^-^ CD127^+^c-Kit^Medium^ Sca-1^Medium^) cells FACS-sorted from Raptor Ctrl/cKO BM were seeded. The co-culturing medium was additionally supplemented with 2 ng/ml murine recombinant IL-3, 2 ng/ml murine recombinant IL-6, 20 ng/ml murine recombinant SCF, 10 ng/ml murine recombinant Flt3L and 5 ng/ml murine recombinant IL-7 (all from R and D Systems). Lenti viral particles were produced in HEK 293 T cells (ATCC Cat\# CRL-3216, RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)) by transiently co-transfecting control vector pWPI (Plasmid \#12254, Addgene), or pWPI-Myb (cDNA of *Myb* was purchased from Dharmacon of GE Lifesciences, Catalog Number: MMM1013-202763262; Clone ID: 3672769) together with helper plasmids pMD2.G (Plasmid \#12259, Addgene) and psPAX2 (Plasmid \#12260, Addgene) using FuGENE HD Transfection Reagent (Promega). OP9 cells were replaced every 3--4 days by transferring co-culturing cells to new plates pre-coated with fresh OP9 cells. The hematopoietic cells in suspension were harvested on day 10--14 post seeding and subjected to flow cytometric analyses.

TLR stimulation and inflammatory cytokine assay {#s4-9}
-----------------------------------------------

For in vitro TLR stimulation, fresh BM cells were seeded in a 12-well plate with a density of 4 × 10^6^ cells/ well(1 ml medium/well) or in a 48-well plate with a density of 1 × 10^6^ cells/ well (200 μl medium/well). The culture medium was RPMI 1640 (Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone), 100 units/ml of penicillin and 100 µg/ml of streptomycin (Gibco). BM cells were stimulated with 1 μg/ml LPS (Sigma-Aldrich, from O111:B4 *E.coli*) or a panel of TLR agonists (InvivoGen) for 16 hr. For intracellular cytokine staining, the protein transport inhibitor Brefeldin A (eBioscience) was added to the culturing medium during the last 4 hr of incubation.

The concentrations of the TLR agonists for in vitro studies were as following: TLR1/2-Pam3CSK4, 300 ng/ml; TLR2-HKLM, 10^8^ cells/ml; TLR3-pIpC(HMW), 10 μg/ml; TLR4-LPS-EK, 1 μg/ml; TLR5-FLA-ST, 1 μg/ml; TLR6/2-FSL-1, 100 ng/ml; TLR7-ssRNA-DR/LyoVec, 1 μg/ml; TLR9-ODN1826, 1 μM. For in vivo tests, pIpC (GE Healthcare, 2 mg/kg), LPS (from O55:B5 *E.coli*, Sigma-Aldrich, 5 mg/kg) and Acetaminophen (Children's TYLENOL, 3.2 mg/mouse) were injected i.p. Supernatant from in vitro cultured BM cells and serum from in vivo treated mice were assayed for inflammatory cytokines by BD Cytometric Bead Array (CBA)-Mouse Inflammation Kit according to the manufacturer\'s protocols.

cDNA library preparation and RNA sequencing {#s4-10}
-------------------------------------------

FACS-sorted CD11b^+^ Gr-1^-^ BM cells from Raptor cKO mice and whole BM cells from Raptor Ctrl mice were used for RNA isolation with TRIzol Reagent (Life Technologies) per manufacturer's instructions. The cDNA libraries were constructed following the standard Illumina protocols by TruSeq RNA and DNA sample preparation kits (Illumina). Briefly, beads containing oligo (dT) were used to isolate poly(A) mRNA from total RNA. Purified mRNA was then fragmented in fragmentation buffer. Using these short fragments as templates, random hexamer-primers were used to synthesize the first-strand cDNA. The second-strand cDNA was synthesized using buffer, dNTPs, RNase H and DNA polymerase I. Short double-stranded cDNA fragments were purified for end repair and the addition of an 'A' base. Next, the short fragments were ligated to Illumina sequencing adaptors. DNA fragments of a selected size were gel-purified and amplified by PCR. The amplified cDNA libraries were quality validated and then subjected to 50 nt single-end sequencing on an Illumina HiSeq 2000 at the University of Michigan DNA Sequencing Core.

RNA-seq gene expression analysis {#s4-11}
--------------------------------

The reference sequences used were genome and transcriptome sequences downloaded from the UCSC website (version mm10). Clean reads were respectively aligned to the reference genome and transcriptome using Tophat (RRID:[SCR_013035](https://scicrunch.org/resolver/SCR_013035)) ([@bib38]). No more than two mismatches were allowed in the alignment for each read. Reads that could be uniquely mapped to a gene were used to calculate the expression level. The gene expression level was measured by the number of uniquely mapped reads per kilobase of exon region per million mappable reads (RPKM) and was calculated by DEGseq (RRID:[SCR_008480](https://scicrunch.org/resolver/SCR_008480)) ([@bib83]). The formula was defined as below:$$RPKM = \frac{10^{6}\ C}{\frac{NL}{10^{3}}}$$

in which C was the number of reads uniquely mapped to the given gene; N was the number of reads uniquely mapped to all genes; L was the total length of exons from the given gene. For genes with more than one alternative transcript, the longest transcript was selected to calculate the RPKM.

PCA, differential and cell-specific expression analysis {#s4-12}
-------------------------------------------------------

The RPKM method eliminates the influence of different gene lengths and sequencing discrepancies on the gene expression calculation. Therefore, the RPKM value can be used for comparing the differences in gene expression among samples. The RPKM value of all RNA-seq raw data were calculated according to the same workflow as stated above.

A function was implemented in the R software to perform principal component analysis (PCA). This function computes the eigenvalues and eigenvectors of the dataset (23498 genes) using the correlation matrix. The eigenvalues were then ordered from highest to lowest, indicating their relative contribution to the structure of the data. The projection of each sample defined by components was represented as a dot plot to generate the PCA figures.

Selected samples were then pooled by subtypes and a two sided t-test with FDR (False discovery rate) of 0.05 and fold change of 4 was performed to identify differentially expressed genes between IMLECs and other subtypes (mean RPKM values of genes in two subtypes both below five were deleted). For subtype-specific genes identified, a one-sided t-test (null hypothesis is greater) was performed with FDR of 0.01 and fold change of 4 contrasting each subtype in turn versus all other subtypes pooled, and statistically significant genes were assigned to the respective subtype signature.

RNA-seq datasets in this study have been deposited in the Gene Expression Omnibus (GEO) database as accession number GSE67863. Other public RNA-seq datasets used are as followings: peritoneal CD11b^+^F4/80^+^ macrophages (GSM1103013, GSM1103014 in GEO Series GSE45358); normal BM CD11b^+^ Gr-1^+^ granulocytes (GSM1166354, GSM1166355, GSM1166356 in GEO Series GSE48048); BM-derived dendritic cells (GSM1012795, GSM1012796 and GSM1012797 in GEO Series GSE41265); BM erythroid cells (GSM1208164, GSM1208165 and GSM1208166 in GEO Series GSE49843); BM pro B and pre B cells (GSM978778 and GSM978779 in GEO Series GSE39756); Naïve B cells (GSM1155172, GSM1155176, GSM1155180 and GSM1155184 in GEO Series GSE47703); activated B cells (GSM1155170, GSM1155174, GSM1155178 and GSM1155182 in GEO Series GSE47703); CD4 T cells, CD8 T cells and natural regulatory T (nTreg) cells (GSM1169492, GSM1169501, GSM1169493, GSM1169502, GSM1169499 and GSM1169508 in GEO Series GSE48138);. Spleen NK cells (GSM1257953, GSM1257954, GSM1257955 and GSM 1257956 in GEO Series GSE52047); Blood neutrophils (GSM1340629, GSM1340630, GSM1340631 and GSM1340632 in GEO Series GSE55633); Lung basophils and eosinophils (GSM1358432, GSM1358433, GSM1358436 and GSM1358437 in GEO Series GSE56292). RNA-seq data on ex vivo DC subsets are obtained from GEO Series GSE62704: GSM1531794 (CDP), GSM1531795 (pDC), GSM1531796 (preDC), GSM1531797 (DN DC), GSM1531798 (CD4^+^ DC), GSM1531799 (CD8^+^ DC).

Genome browser display of immunoglobulin expression {#s4-13}
---------------------------------------------------

To facilitate the global viewing of transcript structure and gene expression quantity of immunoglobulin, an interface in which RNA-seq gene expression of immunoglobulin can be viewed in Genome Browser display was constructed. For viewing and analysis, the UCSC Genome Browser (<http://www.genome.ucsc.edu>, RRID:[SCR_005780](https://scicrunch.org/resolver/SCR_005780)) ([@bib36]) with the mm10 version of the mouse genome was used. For each base in each cell type, the normalized number of aligned reads count was defined as below:$${Normalized\ number\ of\ aligned\ reads\ count = A \ast}\frac{\sum\limits_{k = 0}^{n}\ N_{k}}{n}$$

in which N was the number of reads uniquely mapped to the given base in each cell type; n was the number of replicates for each cell type samples; A was a constant t in which takes the value of 3.5E + 7. The normalized number of aligned reads count for each base in each cell type was stored as WIG file and was uploaded to UCSC genome browser. For each track, y-axis depicted the normalized number of aligned reads count and x-axis depicts physical distance in bases along the chromosome.

Statistical analysis {#s4-14}
--------------------

All the data are presented as mean ±SD. Unless otherwise indicated, two-tailed, unpaired student's *t* tests were used for comparison between two experimental groups. In [Figure 8I](#fig8){ref-type="fig"} and [Figure 8J](#fig8){ref-type="fig"}, where the data do not follow normal distribution, Mann-Whitney tests were used. The log-rank tests were used for the Kaplan-Meier survival analysis. Statistical significance was determined as p\<0.05 (\*p\<0.05; \*\*p\<0.01; \*\*\*p\<0.001).

Funding Information
===================

This paper was supported by the following grants:

-   http://dx.doi.org/10.13039/100000060National Institute of Allergy and Infectious Diseases AI64350 to Yang Liu, Pan Zheng.

-   http://dx.doi.org/10.13039/100000054National Cancer Institute CA183030 to Yang Liu.

-   http://dx.doi.org/10.13039/100000049National Institute on Aging AG036690 to Pan Zheng.

-   http://dx.doi.org/10.13039/100000054National Cancer Institute CA171972 to Yang Liu.

We thank Dr. Hans Schreiber (University of Chicago) and all the colleagues in our laboratory for their helpful discussions, and Ms. Morgan E Daley for editorial assistance. This work was supported by the grants from National Institute of Health AG036690, AI64350, CA183030 and CA171972. This work was initiated at the University of Michigan then completed at Children's Research Institute of Children's National Medical Center.

Additional information {#s5}
======================

No competing interests declared.

Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing---original draft.

Resources, Data curation, Software, Formal analysis, Validation, Investigation.

Data curation, Investigation, Methodology.

Data curation, Methodology.

Methodology.

Methodology.

Resources.

Resources.

Resources, Methodology.

Resources, Methodology.

Resources, Methodology.

Conceptualization, Formal analysis, Supervision, Funding acquisition, Validation, Visualization, Project administration, Writing---review and editing.

Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Visualization, Methodology, Project administration, Writing---review and editing.

Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All of the animals were handled according to approved institutional animal care and use committee (IACUC) protocols (312-13-12 and \#00030574) of the Children\'s National Medical Center. Every effort was made to minimize suffering.

Additional files {#s6}
================

10.7554/eLife.32497.022

###### Transcript levels of CD markers analyzed from RNA-seq datasets.

The FPKM values of 3 mice samples for cKO-IMLEC group (*Rptor* cKO CD11b^+^Gr-1^-^ BM IMLECs) and Ctrl-WBM group (Ctrl whole BM cells) are shown. Fold change indicates the ratio of average FPKM values.
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###### Expression levels of miRNAs targeting *Myb* in Raptor Ctrl and cKO BM HSPCs.

The normalized signal values of 3 mice samples for cKO-HSPCs group and Ctrl-HSPCs group are shown. The microarray data have been deposited to NCBI GEO database with accession number GSE64042 as previously reported ([@bib87]).
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###### Sequences of DNA primers used in PCR assays.
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Major datasets {#s7}
--------------
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: a previous version of this study was rejected after peer review, but the authors submitted for reconsideration. The first decision letter after peer review is shown below.\]

Thank you for submitting your work entitled \"A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

The following individual involved in the review of your submission has agreed to reveal his identity: (peer reviewer: Frederic Geissman).

While your study was thought to be interesting and thought-provoking by all reviewers, you will see that they all share major concerns about the characterization of WT \'IMLECs\', and feel that without far more analysis and characterization of the so-called WT IMLECs, the report presented here does not warrant a case for them in normal myelopoiesis. The extent of additional work involved to address this concern would be far too much to be practical within a two-month revision window.

The reviewers also think that your demonstration of the \'Raptor-deletion-induced IMECs\' and their potential role in pathogenic myeloid differentiation, particularly in specific situations of inflammatory pathology such as in patients with mutations in relevant pathways or in situations of long-term MTORC1 inhibition therapy, could be very interesting independent of any claims about identification of \'WT IMLECs\'. However, as you will see from the reviews, they remain concerned that the present manuscript does not provide adequate clarity about the inflammatory impact of these specific cells in such situations and about the mechanisms involved. Of course, such a manuscript would be quite different from the present one, and will be considered as a new submission subject to a fresh and completely independent review process.

Reviewer \#1:

The manuscript shows very interesting data demonstrating the characteristics of an odd innate myelo-lymphoid cell population in the normal mouse bone marrow that becomes very prominent in the bone marrow of the Raptor-deficient mouse, along with some data regarding the genesis and the functional consequences of this population. These are putatively novel findings and well worth publication. However, enthusiasm for publication would be enhanced if major concerns as identified below could be substantively addressed.

1\) The manuscript focuses far too much on the issue of the role of cell numbers in regulating self-tolerance, as well as on the so-called \'novelty\' of this cell population. While the first question is interesting, it is quite peripheral to the findings in the manuscript. The second claim of novelty somewhat over-interprets the data, which currently address the characterisation, genesis and functions of an identifiable group of leukocytes without actually quite identifying a stable differentiated cell lineage with normal physiological role/s.

2\) The use of polyIC as an inducer of Cre-mediated gene deletion introduces a substantial potential confounder in an analysis of a putative myeloid cell subset. It would be advisable to have confirmatory data for most critical findings using another system of inducible Cre expression, such as the ER-Cre the authors have used.

3\) The claim of the putative \'IMLECs\' being present in wild-type bone marrow needs somewhat more robust support. Thus, the flow cytometric data showing such cells in normal bone marrow indicate two distinct populations in the gate, one CD11b^dull^PDL1^bright^ and one CD11b^bright^PDL1^dull^, neither of which precisely corresponds to the population in Raptor-deficient bone marrow cells. Upon differentiation in vitro, too, WT LSKs and CMPs generate apparent \'IMLECs\' that show much lower levels of PD-L1 than Raptor-deficient \'IMLECs\' do. Also, the data on TLR/PRR and cytokine expression on \'IMLECs\' from WT bone marrow again show that these cells are PDL1low compared to \'IMLECs\' from Raptor-deficient mice, and that they are less efficient at producing TNF-α. Greater clarity in the similarities and differences in this cell population from wild-type versus Raptor-deficient mice, both in terms of cell-surface phenotype and transcript profiles, is needed.

4\) The finding that LysM-Cre-mediated rptor deletion does not lead to the generation of the putative IMLECs needs further explanation, since a substantial proportion of CMPs would be expected to express LysM-Cre and would therefore be expected to be redirected into an IMLEC differentiation pathway per the authors\' model. It is thus possible that altered commitment is programmed prior to the CMP stage. This is further complicated by the fact that, while mixed chimeras using whole bone marrow cells generate Raptor-deficient myeloid cells that are mostly \'IMLECs\' rather than granulocytic cells, this is not true when LSKs are used; Raptor-deficient LSK cells give rise mostly to granulocytic cells in vivo. It is possible that this differentiation pathway is imprinted as a result of the absence of Raptor in a very early hematopoietic cell stage leading to some degree of loss of myeloid/lymphoid distinction as well as downstream loss of granulocytic differentiation. Acknowledgement and some explanation of these ambiguities are essential.

5\) The c-Myb-deletion data require further support. The phenotype of the heterozygous c-Myb-deleted mouse with reference to PDL1 expression needs to be shown. Also, the connection between c-myb and Raptor deficiencies in generating these putative IMLECs requires clarity; thus, for example, does provision of heterologous c-myb modify the generation of \'IMLECs\' from Raptor-deficient LSK cells in vitro?

6\) The claim that the explanation for the disease phenotype in vivo in Raptor-deficient mice solely or even primarily lies in the abnormally large numbers of normally functioning highly sensitive pro-inflammatory \'IMLECs\' needs much more substantiation. At the very least, mixed bone marrow chimeras with graded contributions from Raptor-deficient and WT bone marrow need to be done to examine the disease consequences when Raptor-deficient \'IMLEC\' cell numbers approach their apparent WT counterparts.

Reviewer \#2:

Research article -- Tang et al. A population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1

The authors report a previously uncharacterized leukocyte subset (Lin-, CD11b+, Gr1-, PD-L1+) expressing IgH and Rag2, they name IMLEC. IMLEC are present in the bone marrow of Rptor deficient, pIpc treated mice, as well, in much lower numbers in the BM of Rptor ^F/F^, pIpc treated mice. The authors also show the presence of cells with similar features in the spleen BM and blood of wt mice. When genetic deletion of *Rptor* or *Myb* is introduced in Mx1-Cre expressing cells the population expands dramatically, in a cell-autonomous manner. IMLEC are also present in the progeny of Myb-deficient hematopoietic progenitors. IMLEC produce cytokines in response to TLR stimulation, and accumulate in tissues. The authors conclude that mTOR is able to suppress IMLEC expansion via *Myb* (in a relatively mysterious manner), and when mTOR is dysregulated, IMLEC production can lead to severe pathological consequences due to a high vulnerability of IMLECs to TLR ligands.

The experiments are well performed, the authors analyze IMLECs in depth and describe how genetic dysregulation of hematopoietic cells can lead to the aberrant expansion of these dysfunctional myelo/lymphoid cells. The main interrogation about this study, is whether this cell type is physiological, or only appears in the absence of Rptor or Myb. The characterization of \'WT\' IMLEC is not convincing. Nevertheless, this study indicates how cell autonomous genetic events in hematopoietic progenitors can lead to inflammation, by the generation of \'abnormal\' myeloid cells.

Altogether, this study is interesting and well performed, but the description of a new physiological cell type is not convincing, and the manuscript could be revised to focus on the \'pathological\' consequences of Raptor deficiency.

The claim of the paper describing WT IMLEC as a cell type is not convincing, and extensive experiments would be needed if the authors were to maintain this claim.

This work is however very interesting as there was evidence in particular in a recent article in Cell by the group of M. Karin that \'long term mTORC1 inhibition\' (in this model raptor deletion, or rapamycin treatment) in vivo induces inflammation, and this pathway is of obvious relevance as longterm rapamycin treatment is used or maybe(?) misused in human. The authors observations may support the provocative findings of Karin, and provide an (alternative) or complementary mechanism for this important observation.

Specific comments:

[Figure 1D](#fig1){ref-type="fig"}: It is, just by looking at the HE stain, not possible to appreciate the expansion of the lymphocyte population. Controls would need to be displayed bigger. (see also comment for [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}

[Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}: Display control spleen in the same way as the Rptor-/- spleen (comparable to liver in [Figure 8C](#fig8){ref-type="fig"} where control and experimental animals are shown in the same magnifications)

[Figure 1---figure supplement 4A, B](#fig1s4){ref-type="fig"}: ST-HSCs are CD150- and CD48-, please revise the FACS plots and the quantification in B

[Figure 3D](#fig3){ref-type="fig"}: Sorted wild-type IMLECs do not look exactly as Rptor-deficient IMLECs (shown in [figure 1F](#fig1){ref-type="fig"}). This brings back the concern mentioned above of whether these cells are the same cell type, or whether the KO changes the phenotypic nature of WT IMLECs. The authors should at least sort and stain Ctrl and KO cells at the same time to see whether these histological differences are not due to technical reasons. It would be also of interest to see these cells in comparison in histograms showing their FSC and SSC sizes as shown in [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}.

[Figure 3E](#fig3){ref-type="fig"}: The authors speculate about the CD11chigh population in the liver, which could be CD8^+^ DCs. Since these are WT samples, it would be reasonable to repeat this experiment and include CD8 in the lineage or to define these populations further.

[Figure 5F](#fig5){ref-type="fig"}: The authors should either (always) speculate that miRNAs might be the reason for Myb downregulation in Rptor^-/-^ mice, or (always) strongly state it. For now, it seems that the authors could not decide as their statements change in the text and the figure legends.

Reviewer \#3:

Tang et al. described here a previously reported population of cell expanded in a mouse model presenting an inactivation of the mTOR Complex 1. These cells present a lymphoid morphology with a myeloid phenotype, clustering with macrophages at the gene expression level. They also express a wide range of TLR and are functional, secreting pro-inflammatory cytokines when challenged.

The main concern here is that the nature of the cell population remains elusive especially in the WT environment: is it a real independent lineage? Is it a \"blocked and frustrated\" progenitor stage? Most importantly, its physiological relevance is also not addressed since this population is seen mostly when deleting Rptor in hematopoietic stem/progenitor cells and as its existence in WT bone marrow is really not convincingly addressed. It rather appears as a blocked and dysfunctional dead end of abnormal hematopoiesis that does not exist in normal hematopoiesis. Again, the authors do not provide enough convincing data supporting the significance of this population.

In term of phenotype, the authors found that IMLEC express PD-L1 and CD11b. Do they express other markers such as Ly6C? MHC-II? Of note, CD11b is indeed a myeloid marker but also express by lymphoid cells such as NK cells and cannot really be used as a lineage marker. In addition, among the 317 CD markers described in [Supplementary file 1](#supp1){ref-type="supplementary-material"}, the authors should test other markers than PDL1. Also, since these markers where found from the KO IMLEC, any risk that some of the negative markers tested are controlled by functional mTOR complex? Phenotype should be tested in WT bone marrow.

The authors used RNAseq data to investigate the nature of the cells. However, they isolated IMLEC from Rptor deficient bone marrow and hence, the lack of functional mTOR could blur the true nature of the cells. The authors should perform gene expression profiling using WT cells. Also, it is not clear in the comparison of gene expression profiles of KO IMLEC with other known subsets of hematopoietic cells if the authors sorted the cells for the other known subsets from KO, WT mice or use only public database. If the latter, they should precise if all these arrays were made with a comparable approach using similar aged and sex match mice of the same background.

The characterization of the WT IMLEC is not convincing at all and the data provided mostly correlative. How comparable are the WT and KO populations in phenotype, gene expression profile, TLR expression and function.

The statement \"Perhaps the CD11c^high^ cells in the spleen are the CD8^+^ PDL-1^+^ DCs and the CD11c^low/-^ cells are IMLECs.\" is not acceptable. The authors should prove it.

To identify the progenitor that may give rise to IMLECs, the authors omitted to test the contribution of CLP, which will be important to test as CLP give rise to B cells and IMLEC present high levels of sterile transcripts thay may suggest that they correspond to a stage before early B cell commitment.

How do the authors exclude that the broad expression of TLR could be a response to induction of Mx1 by pIpC administration?

For the Ki67 and annexin stainings, the authors are comparing IMLEC to the rest of the bone marrow, which is a mix of heterogeneous population of progenitors and differentiated cells. This is not really comparable and not relevant. For proliferation, the authors should rather do a Brdu labeling or cell cycle assay by flow cytometry that measure DNA content (and which is more accurate and sensitive than Ki67 staining).

\[Editors' note: what now follows is the decision letter after the authors submitted for further consideration.\]

Thank you for submitting your article \"A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors and the evaluation has been overseen by Tadatsugu Taniguchi as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript is an extensively revised re-submission of an earlier version showing very interesting data demonstrating the characteristics of an odd innate myelo-lymphoid cell population in the normal mouse bone marrow that becomes very prominent in the bone marrow of the Raptor-deficient mouse, along with some data regarding the genesis and the functional consequences of this population. These are putatively novel findings and well worth publication. The authors have made efforts to address any, though not all, of the concerns expressed regarding the earlier version. Some reservations do, however, remain.

Essential revisions:

1\) Specifically, it is still not quite clear if the data indicate a stable differentiated cell lineage with normal physiological role/s, and/or a specific non-redundant role in the inflammatory phenotype seen in Rptor-deficient mice. The characterisation of the IMLECs in WT mice remains preliminary and is not fully convincing, making it unclear if they really exist as a homogeneous population in normal bone marrow. The massive generation of IMLEC following Myb deletion (revised [figure 6](#fig6){ref-type="fig"}) further and strongly suggests that IMLEC may be some kind of a preleukemic cell type. It is not clear if WT IMLECs preserve their phenotype stably in vivo, and if induced deletion of Rptor in them lead to further, putatively aberrant differentiation. Therefore, the manuscript needs to acknowledge these issues and substantially modulate the claims to identification of a new \'normal\' bone marrow cell type in a far more modest and qualified direction.

2\) More convincingly, the study indicates how cell autonomous genetic events in hematopoietic progenitors can lead to inflammation by the generation of \'abnormal\' myeloid cells. That issue, too, will be strengthened by demonstrations of the disease-related consequences of WT and/or Rptor-deficient IMLECs.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1 in Mice\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor), a Reviewing editor.

The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:

The authors have addressed the revisions advised in the earlier decision to some extent. However, it is essential to make further major and extensive text modifications (1) to reflect the primary focus of the manuscript on the disease-related role/s of Rptor-deficient IMLECs, and (2) to make it much more clear that the provenance of the IMLEC-like population found in WT mice is quite unclear at the moment.

10.7554/eLife.32497.055

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

> Reviewer \#1:
>
> The manuscript shows very interesting data demonstrating the characteristics of an odd innate myelo-lymphoid cell population in the normal mouse bone marrow that becomes very prominent in the bone marrow of the Raptor-deficient mouse, along with some data regarding the genesis and the functional consequences of this population. These are putatively novel findings and well worth publication. However, enthusiasm for publication would be enhanced if major concerns as identified below could be substantively addressed.

We appreciate the expert evaluation and recommendation of publication of our work. We performed feasible experiments and made corresponding figure/text amendment to address the major concerns, as detailed below:

> 1\) The manuscript focuses far too much on the issue of the role of cell numbers in regulating self-tolerance, as well as on the so-called \'novelty\' of this cell population. While the first question is interesting, it is quite peripheral to the findings in the manuscript. The second claim of novelty somewhat over-interprets the data, which currently address the characterisation, genesis and functions of an identifiable group of leukocytes without actually quite identifying a stable differentiated cell lineage with normal physiological role/s.

We appreciate the comments and performed additional experiments to extensively characterize the corresponding population in the wild type mouse. Although with an extremely low abundance, the WT IMLECs were proven to display same morphology, size and granularity, expression for sterile transcripts of Ig loci ([Figure 4](#fig4){ref-type="fig"}), comparable levels of TLR expression ([Figure 7](#fig7){ref-type="fig"}), much similar extents of specific transcription factors expression ([Figure 4](#fig4){ref-type="fig"}), comparable ability in TNF production ([Figure 7](#fig7){ref-type="fig"}). These data demonstrated that IMLEC existed under physiological condition at low numbers and thus support the notion that Raptor deletion increases IMLEC population size rather than creates a new cell population. As such, we believe it is reasonable to state that the new function of Raptor described herein is to prevent expansion of IMLEC under physiological conditions, and in doing so, it prevents pathological consequences associated with IMLEC expansion.

We would like to cast the new findings in the context of adaptive and innate immune regulatory mechanisms. However, we do understand the reviewer's preference, and carefully revised the text to reflect the reviewer's advice.

> 2\) The use of polyIC as an inducer of Cre-mediated gene deletion introduces a substantial potential confounder in an analysis of a putative myeloid cell subset. It would be advisable to have confirmatory data for most critical findings using another system of inducible Cre expression, such as the ER-Cre the authors have used.

Rptor^F/F^, CreER mice were generated. Same phenotypes were observed in BM cells from both regular Rptor^F/F,^ CreER mice and recipient mice with Rptor^F/F^, CreER BM transplantation, after tamoxifen induced Rptor deletion ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}).

> 3\) The claim of the putative \'IMLECs\' being present in wild-type bone marrow needs somewhat more robust support. Thus, the flow cytometric data showing such cells in normal bone marrow indicate two distinct populations in the gate, one CD11b^dull^PDL1^bright^ and one CD11b^bright^PDL1^dull^, neither of which precisely corresponds to the population in Raptor-deficient bone marrow cells. Upon differentiation in vitro, too, WT LSKs and CMPs generate apparent \'IMLECs\' that show much lower levels of PDL1 than Raptor-deficient \'IMLECs\' do. Also, the data on TLR/PRR and cytokine expression on \'IMLECs\' from WT bone marrow again show that these cells are PDL1low compared to \'IMLECs\' from Raptor-deficient mice, and that they are less efficient at producing TNF-α. Greater clarity in the similarities and differences in this cell population from wild-type versus Raptor-deficient mice, both in terms of cell-surface phenotype and transcript profiles, is needed.

Additional experiments were performed to more extensively characterize IMLECs from wild type mice ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}; [Figure 4B](#fig4){ref-type="fig"}, [Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 7B](#fig7){ref-type="fig"}). In toto, we presented evidence for IMLEC in WT mice from the following aspects: (i) Morphology (Giemsa staining, [Figure 4](#fig4){ref-type="fig"}); (ii) Size (FSC) and granularity(SSC) ([Figure 4](#fig4){ref-type="fig"}); (iii) expression for sterile transcripts of Ig loci (qPCR, [Figure 4](#fig4){ref-type="fig"}); (iv) More surface markers other than revealed before (flow cytometry, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (v) TLRs expression (qPCR, [Figure 7](#fig7){ref-type="fig"}); (vi) Population specific transcriptional factors (qPCR, [Figure 4](#fig4){ref-type="fig"}); (vii) Apoptosis (Annexin A/7-AAD staining) and Proliferation (Ki-67/BrdU incorporation)([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (viii) TNF production in vitro (intracellular flow staining, [Figure 7](#fig7){ref-type="fig"}). Further clarification of the similarities and differences (such as PD-L1 expression intensity) between IMLECs originated from WT and Raptor-deficient mice BM was stated in the current manuscript.

> 4\) The finding that LysM-Cre-mediated rptor deletion does not lead to the generation of the putative IMLECs needs further explanation, since a substantial proportion of CMPs would be expected to express LysM-Cre and would therefore be expected to be redirected into an IMLEC differentiation pathway per the authors\' model. It is thus possible that altered commitment is programmed prior to the CMP stage. This is further complicated by the fact that, while mixed chimeras using whole bone marrow cells generate Raptor-deficient myeloid cells that are mostly \'IMLECs\' rather than granulocytic cells, this is not true when LSKs are used; Raptor-deficient LSK cells give rise mostly to granulocytic cells in vivo. It is possible that this differentiation pathway is imprinted as a result of the absence of Raptor in a very early hematopoietic cell stage leading to some degree of loss of myeloid/lymphoid distinction as well as downstream loss of granulocytic differentiation. Acknowledgement and some explanation of these ambiguities are essential.

Since LSK also contained LT-HSC and ST-HSC, the difference between whole bone marrow and LSK does not necessarily suggest IMLEC comes from earlier progenitors. Rather, we think the generation of granulocytes from LSK relates to the short-term transplantation protocol designed to study progenitors. LSK was used as positive control.

Transplantation of progenitor cells in the context of induced deletion is difficult because the progenitor cells do not self-renew and thus could further differentiate before the deletion effect. We believe some, although most likely not all, CMP can generate IMLEC based on in vitro co-culture and in vivo transplantation studies. This does not exclude other possibilities, as detailed in revised texts.

> 5\) The c-Myb-deletion data require further support. The phenotype of the heterozygous c-Myb-deleted mouse with reference to PDL1 expression needs to be shown. Also, the connection between c-Myb and Raptor deficiencies in generating these putative IMLECs requires clarity; thus, for example, does provision of heterologous c-Myb modify the generation of \'IMLECs\' from Raptor-deficient LSK cells in vitro?

Mice with heterozygous c-Myb deletion (Myb^F/+^, Mx1-Cre) did not show significant accumulation of IMLECs ([Figure 6---figure supplement 1A-C](#fig6s1){ref-type="fig"}). However, deletion of c-Myb in mice with homozygous floxed c-Myb (Myb^F/F^, Mx1-Cre) did show obvious increase of PD-L1 expression in CD11b^+^Gr-1^-^ BM cells ([Figure 6C](#fig6){ref-type="fig"}, [Figure 6D](#fig6){ref-type="fig"}, [Figure 6E](#fig6){ref-type="fig"}). The provision of heterologous c-Myb significantly diminished the generation of IMLECs from Raptor-deficient LSK cells in our in vitro OP9 co-culturing experiments ([Figure 6---figure supplement 1D-G](#fig6s1){ref-type="fig"}).

> 6\) The claim that the explanation for the disease phenotype in vivo in Raptor-deficient mice solely or even primarily lies in the abnormally large numbers of normally functioning highly sensitive pro-inflammatory \'IMLECs\' needs much more substantiation. At the very least, mixed bone marrow chimeras with graded contributions from Raptor-deficient and WT bone marrow need to be done to examine the disease consequences when Raptor-deficient \'IMLEC\' cell numbers approach their apparent WT counterparts.

Even when more mutant BM is provided in competitive reconstitution assays ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5B](#fig5){ref-type="fig"}, and also unpublished data) and others (*Cell Stem Cell*, 2012: 11, 429--439), the Raptor-deficient hematopoietic stem cells are drastically inferior to Raptor-sufficient hematopoietic stem cells in giving rise to progenies in mixed BM chimeras. The WT BM-derived cells will be overwhelmingly dominant and the contribution of Rptor^-/-^ IMLECs cannot be evaluated in this mixed BM model. We also attempted to transfer Rptor^-/-^ IMLECs into Rag1^-/-^ mice but these cells did not survive in vivo. As a result, we were not able use adoptive transfer to substantiate pathogenicity of IMLEC.

On the other hand, we have presented data that IMLEC produce high levels of cytokines which are known to be pathogenic in mice.

We have now carefully discussed this issue to reflect the reviewer's concern.

> Reviewer \#2:
>
> The authors report a previously uncharacterized leukocyte subset (Lin-, CD11b+, Gr1-, PD-L1+) expressing IgH and Rag2, they name IMLEC. IMLEC are present in the bone marrow of Rptor deficient, pIpc treated mice, as well, in much lower numbers in the BM of Rptor ^f/f^, pIpc treated mice. The authors also show the presence of cells with similar features in the spleen BM and blood of wt mice. When genetic deletion of Rptor or Myb is introduced in Mx1-Cre expressing cells the population expands dramatically, in a cell-autonomous manner. IMLEC are also present in the progeny of Myb-deficient hematopoietic progenitors. IMLEC produce cytokines in response to TLR stimulation, and accumulate in tissues. The authors conclude that mTOR is able to suppress IMLEC expansion via Myb (in a relatively mysterious manner), and when mTOR is dysregulated, IMLEC production can lead to severe pathological consequences due to a high vulnerability of IMLECs to TLR ligands.

We appreciate the expert evaluation of our work.

> The experiments are well performed, the authors analyze IMLECs in depth and describe how genetic dysregulation of hematopoietic cells can lead to the aberrant expansion of these dysfunctional myelo/lymphoid cells. The main interrogation about this study, is whether this cell type is physiological, or only appears in the absence of Rptor or Myb. The characterization of \'WT\' IMLEC is not convincing. Nevertheless, this study indicates how cell autonomous genetic events in hematopoietic progenitors can lead to inflammation, by the generation of \'abnormal\' myeloid cells.
>
> Altogether, this study is interesting and well performed, but the description of a new physiological cell type is not convincing, and the manuscript could be revised to focus on the \'pathological\' consequences of Raptor deficiency.

Additional experiments were performed to more extensively characterize IMLECs from wild type mice ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}; [Figure 4B](#fig4){ref-type="fig"}, [Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"}; [Figure 4 ---figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 7B](#fig7){ref-type="fig"}). In toto, we presented evidence for IMLEC in WT mice from the following aspects: (i) Morphology (Giemsa staining, [Figure 4](#fig4){ref-type="fig"}); (ii) Size (FSC) and granularity(SSC) ([Figure 4](#fig4){ref-type="fig"}); (iii) expression for sterile transcripts of Ig loci (qPCR, [Figure 4](#fig4){ref-type="fig"}); (iv) More surface markers other than revealed before (flow cytometry, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (v) TLRs expression (qPCR, [Figure 7](#fig7){ref-type="fig"}); (vi) Population specific transcriptional factors (qPCR, [Figure 4](#fig4){ref-type="fig"}); (vii) Apoptosis (Annexin A/7-AAD staining) and Proliferation (Ki-67/BrdU incorporation)([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (viii) TNF production in vitro(intracellular flow staining, [Figure 7](#fig7){ref-type="fig"}). Further clarification of the similarities and differences (such as PD-L1 expression intensity) between IMLECs originated from WT and Raptor-deficient mice BM was stated in the current manuscript.

> The claim of the paper describing WT IMLEC as a cell type is not convincing, and extensive experiments would be needed if the authors were to maintain this claim.
>
> This work is however very interesting as there was evidence in particular in a recent article in Cell by the group of M. Karin that \'long term mTORC1 inhibition\' (in this model raptor deletion, or rapamycin treatment) in vivo induces inflammation, and this pathway is of obvious relevance as longterm rapamycin treatment is used or maybe(?) misused in human. The authors observations may support the provocative findings of Karin, and provide an (alternative) or complementary mechanism for this important observation.

The work from Michael Karin et al. was cited and discussed in our current manuscript.

As stated in the manuscript, we have failed to induce IMLECs by mTOR kinase inhibitor Torin2 or rapamycin in WT mice, despite an extensive effort. Therefore, under normal circumstances, pharmaceutical inhibition of mTORC1 alone cannot achieve comparable levels of inflammation. Probably additional conditions must be met for mTOR inhibitors to cause inflammation. However, our findings focused on characterizing IMLECs and inflammation support the provocative findings of Michael Karin *et al.* and might provide alternative and complementary explanations.

> Specific comments:
>
> [Figure 1D](#fig1){ref-type="fig"}: It is, just by looking at the HE stain, not possible to appreciate the expansion of the lymphocyte population. Controls would need to be displayed bigger. (see also comment for [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}
>
> [Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}: Display control spleen in the same way as the Rptor^-/-^ spleen (comparable to liver in [Figure 8C](#fig8){ref-type="fig"} where control and experimental animals are shown in the same magnifications)

Control staining is now in the same magnification as that of cKO in [Figure 1](#fig1){ref-type="fig"} and [Figure 1 -- ---figure supplement 1](#fig1s1){ref-type="fig"}.

> [Figure 1---figure supplement 4A,B](#fig1s4){ref-type="fig"}: ST-HSCs are CD150- and CD48-, please revise the FACS plots and the quantification in B

ST-HSCs are CD150^+^ and CD48^+^, as defined from the publications on SLAM receptors and HSC (*Cell Stem Cell*. 2013 Jul 3;13(1):102-16); *Cell*. 2005 Jul 1;121(7):1109-21), as well as evidenced from previous publication from our laboratory (*J Exp Med.* 2008 Sep 29; 205(10): 2397--2408.).

> [Figure 3D](#fig3){ref-type="fig"}: Sorted wild-type IMLECs do not look exactly as Rptor-deficient IMLECs (shown in [figure 1F](#fig1){ref-type="fig"}). This brings back the concern mentioned above of whether these cells are the same cell type, or whether the KO changes the phenotypic nature of WT IMLECs. The authors should at least sort and stain Ctrl and KO cells at the same time to see whether these histological differences are not due to technical reasons. It would be also of interest to see these cells in comparison in histograms showing their FSC and SSC sizes as shown in [Figure 1---figure supplement 2E](#fig1s2){ref-type="fig"}.

We performed additional studies as advised. Ctrl and cKO IMLECs showed almost identical morphology according to Giemsa staining ([Figure 4A](#fig4){ref-type="fig"}). They also display comparable size and granularity assayed by flow cytometry ([Figure 4B](#fig4){ref-type="fig"}).

> [Figure 3E](#fig3){ref-type="fig"}: The authors speculate about the CD11c^high^ population in the liver, which could be CD8^+^ DCs. Since these are WT samples, it would be reasonable to repeat this experiment and include CD8 in the lineage or to define these populations further.

We removed the statements on speculating CD8^+^ DC from the manuscript.

> [Figure 5F](#fig5){ref-type="fig"}: The authors should either (always) speculate that miRNAs might be the reason for Myb downregulation in Rptor^-/-^ mice, or (always) strongly state it. For now, it seems that the authors could not decide as their statements change in the text and the figure legends.

After revision, the tune on the statement of miRNA and Myb downregulation is consistent in the text and the figure legend in the current manuscript.

> Reviewer \#3:
>
> Tang et al. described here a previously reported population of cell expanded in a mouse model presenting an inactivation of the mTOR Complex 1. These cells present a lymphoid morphology with a myeloid phenotype, clustering with macrophages at the gene expression level. They also express a wide range of TLR and are functional, secreting pro-inflammatory cytokines when challenged.
>
> The main concern here is that the nature of the cell population remains elusive especially in the WT environment: is it a real independent lineage? Is it a \"blocked and frustrated\" progenitor stage? Most importantly, its physiological relevance is also not addressed since this population is seen mostly when deleting Rptor in hematopoietic stem/progenitor cells and as its existence in WT bone marrow is really not convincingly addressed. It rather appears as a blocked and dysfunctional dead end of abnormal hematopoiesis that does not exist in normal hematopoiesis. Again, the authors do not provide enough convincing data supporting the significance of this population.

We appreciate the reviewer's constructive criticism of our work. Additional experiments were performed to more extensively characterize IMLECs from wild type mice ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}; [Figure 4B](#fig4){ref-type="fig"}, [Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 7B](#fig7){ref-type="fig"}). In toto, we presented evidence for IMLEC in WT mice from the following aspects: (i) Morphology (Giemsa staining, [Figure 4](#fig4){ref-type="fig"}); (ii) Size (FSC) and granularity(SSC) ([Figure 4](#fig4){ref-type="fig"}); (iii) expression for sterile transcripts of Ig loci (qPCR, [Figure 4](#fig4){ref-type="fig"}); (iv) More surface markers other than revealed before (flow cytometry, [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (v) TLRs expression (qPCR, [Figure 7](#fig7){ref-type="fig"}); (vi) Population specific transcriptional factors (qPCR, [Figure 4](#fig4){ref-type="fig"}); (vii) Apoptosis (Annexin A/7-AAD staining) and Proliferation (Ki-67/BrdU incorporation)([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}); (viii) TNF production in vitro (intracellular flow staining, [Figure 7](#fig7){ref-type="fig"}). Further clarification of the similarities and differences (such as PD-L1 expression intensity) between IMLECs originated from WT and Raptor-deficient mice BM was stated in the current manuscript

> In term of phenotype, the authors found that IMLEC express PDL1 and CD11b. Do they express other markers such as Ly6C? MHC-II? Of note, CD11b is indeed a myeloid marker but also express by lymphoid cells such as NK cells and cannot really be used as a lineage marker. In addition, among the 317 CD markers described in [Supplementary file 1](#supp1){ref-type="supplementary-material"}, the authors should test other markers than PDL1. Also, since these markers where found from the KO IMLEC, any risk that some of the negative markers tested are controlled by functional mTOR complex? Phenotype should be tested in WT bone marrow.

The surface markers including MHC-I, MHC-II and Ly6C were evaluated by flow cytometry ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). IMLECs are positive for MHC-I and MHC-II, largely negative/low for Ly6C. Among the 317 CD markers, other surface markers (CD14, CD68) with commercially available antibodies were also tested. Since the tested top-high markers have largely comparable expression levels between WT and Rptor^-/-^ IMLECs, the chance for them to be the negatively regulated targets of mTORC1 is low. However, we cannot exclude the possibility that some other candidate markers are really negative markers controlled by mTORC1.

> The authors used RNAseq data to investigate the nature of the cells. However, they isolated IMLEC from Rptor deficient bone marrow and hence, the lack of functional mTOR could blur the true nature of the cells. The authors should perform gene expression profiling using WT cells. Also, it is not clear in the comparison of gene expression profiles of KO IMLEC with other known subsets of hematopoietic cells if the authors sorted the cells for the other known subsets from KO, WT mice or use only public database. If the latter, they should precise if all these arrays were made with a comparable approach using similar aged and sex match mice of the same background.

We used the RNA-seq datasets from CD11b^+^Gr-1^-^ Rptor-deficient IMLECs for mining of potential surface markers, transcription factors to further investigate the nature of this population. Once the key factors are identified, we performed targeted analyses to compare WT and mutant IMLEC. Further validating of WT IMLECS in terms of gene expression profile was performed by comparing the surface markers expression ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), TLR genes expression ([Figure 7B](#fig7){ref-type="fig"}) and population-specific transcription factors ([Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"}).

In addition, as stated in the Materials and methods section, public datasets of various known hematopoietic populations were used for comparison with cKO IMLECS. These datasets were from largely similar age of wild type C57BL/6 mice and compared with a comparable approach. Actually, publicly available datasets were widely used for comparative analysis and integrating to generate new results by researchers worldwide, such as these published papers: *Immunity*. 2014 Sep 18; 41(3):465-77; *Nat Methods*. 2013 Aug; 10 (8):795-803; *Genome Biol.* 2008 Jan 24; 9(1):R17.

> The characterization of the WT IMLEC is not convincing at all and the data provided mostly correlative. How comparable are the WT and KO populations in phenotype, gene expression profile, TLR expression and function.

Additional experiments were performed to more extensively characterize IMLECs from wild type mice ([Figure 4B](#fig4){ref-type="fig"}, [Figure 4D](#fig4){ref-type="fig"}, [Figure 4E](#fig4){ref-type="fig"}; [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}; [Figure 7B](#fig7){ref-type="fig"}).

> The statement \" Perhaps the CD11chigh cells in the spleen are the CD8^+^ PDL-1^+^ DCs and the CD11c^low/-^ cells are IMLECs.\" is not acceptable. The authors should prove it.

CD11c^high^ population in the spleen is clearly dentritic cell population, while IMLECs are CD11c^low/-^. Since dendritic cells comprise a wide range of heterogeneous populations of cells, in order to avoid confusions on defining IMLECs, we removed the statements on speculating CD8^+^ DC from the manuscript.

> To identify the progenitor that may give rise to IMLECs, the authors omitted to test the contribution of CLP, which will be important to test as CLP give rise to B cells and IMLEC present high levels of sterile transcripts thay may suggest that they correspond to a stage before early B cell commitment.

The contribution of CLPs in giving rise to IMLECs was evaluated ([Figure 5E](#fig5){ref-type="fig"}, [Figure 5F](#fig5){ref-type="fig"}). Our data demonstrate that the CLPs have the potential to give rise to IMLECs. We have modified to text to reflect the reviewer's concern.

> How do the authors exclude that the broad expression of TLR could be a response to induction of Mx1 by pIpC administration?

Another inducible deletion system (Rptor^F/F^, CreER mice) was introduced. Same phenotypes were observed in BM cells from both regular Rptor^F/F^, CreER mice and recipient mice with Rptor^F/F^, CreER BM transplantation, after tamoxifen induced Rptor deletion ([Figure 1---figure supplement 5](#fig1s5){ref-type="fig"}).

> For the Ki67 and annexin stainings, the authors are comparing IMLEC to the rest of the bone marrow, which is a mix of heterogeneous population of progenitors and differentiated cells. This is not really comparable and not relevant. For proliferation, the authors should rather do a Brdu labeling or cell cycle assay by flow cytometry that measure DNA content (and which is more accurate and sensitive than Ki67 staining).

Comparisons between IMLECs and other defined lineages were undertaken in terms of apoptosis ([Figure 4---figure supplement 1B](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 1C](#fig4s1){ref-type="fig"}) and proliferation assayed by BrdU incorporation ([Figure 4---figure supplement 1D](#fig4s1){ref-type="fig"}, [Figure 4---figure supplement 1E](#fig4s1){ref-type="fig"}).

\[Editors\' note: the author responses to the re-review follow.\]

> The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

We would like to take this opportunity again to thank the editors and reviewers for their constructive suggestions. We have made necessary changes of text to further acknowledge some issues and concerns from the editors and reviewers, as well as to fully meet the requirements of *eLife* publishing policies. As a result, we believe that the manuscript is greatly strengthened and ready for publication.

> Summary:
>
> The manuscript is an extensively revised re-submission of an earlier version showing very interesting data demonstrating the characteristics of an odd innate myelo-lymphoid cell population in the normal mouse bone marrow that becomes very prominent in the bone marrow of the Raptor-deficient mouse, along with some data regarding the genesis and the functional consequences of this population. These are putatively novel findings and well worth publication. The authors have made efforts to address any, though not all, of the concerns expressed regarding the earlier version. Some reservations do, however, remain.

We appreciate the expert evaluation and recommendation of publication of our work.

> Essential revisions:
>
> 1\) Specifically, it is still not quite clear if the data indicate a stable differentiated cell lineage with normal physiological role/s, and/or a specific non-redundant role in the inflammatory phenotype seen in Rptor-deficient mice. The characterisation of the IMLECs in WT mice remains preliminary and is not fully convincing, making it unclear if they really exist as a homogeneous population in normal bone marrow. The massive generation of IMLEC following Myb deletion (revised [figure 6](#fig6){ref-type="fig"}) further and strongly suggests that IMLEC may be some kind of a preleukemic cell type. It is not clear if WT IMLECs preserve their phenotype stably in vivo, and if induced deletion of Rptor in them lead to further, putatively aberrant differentiation. Therefore, the manuscript needs to acknowledge these issues and substantially modulate the claims to identification of a new \'normal\' bone marrow cell type in a far more modest and qualified direction.

We agree with the suggestions on further acknowledging these issues, and we have now carefully discussed these issues to reflect the editors and reviewers' concerns.

> 2\) More convincingly, the study indicates how cell autonomous genetic events in hematopoietic progenitors can lead to inflammation by the generation of \'abnormal\' myeloid cells. That issue, too, will be strengthened by demonstrations of the disease-related consequences of WT and/or Rptor-deficient IMLECs.

We appreciate the constructive suggestion on strengthening the significance of work by revealing the disease-related consequences of IMLEC population. We have demonstrated the association between the expansion of Rptor-deficient IMLECs and lethal inflammatory responses to TLR ligands in mouse ([Figure 7](#fig7){ref-type="fig"}, [Figure 8](#fig8){ref-type="fig"} and [Figure 9](#fig9){ref-type="fig"}). This is the first report on uncovering the critical innate immune functions of the CD3^-^B220^-^NK1.1^-^Ter119^-^ CD11c^low/-^CD115^-^F4/80^low/-^Gr-1^-^ CD11b^+^PD-L1^+^ population in mouse, and to the best of our knowledge, there is no related clinical report on human IMLECs till now. On the other hand, since RPTOR and MTOR are embryonically lethal genes, it is almost impossible to identify naturally occurring immune cells with completely abrogated mTORC1 activity and patients with genetically predisposed RPTOR/MTOR mutations.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> Thank you for resubmitting your work entitled \"A Population of Innate Myelolymphoblastoid Effector Cell Expanded by Inactivation of mTOR Complex 1 in Mice\" for further consideration at eLife. Your revised article has been favorably evaluated by Tadatsugu Taniguchi (Senior editor), a Reviewing editor.
>
> The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined below:
>
> The authors have addressed the revisions advised in the earlier decision to some extent. However, it is essential to make further major and extensive text modifications (1) to reflect the primary focus of the manuscript on the disease-related role/s of Rptor-deficient IMLECs, and (2) to make it much more clear that the provenance of the IMLEC-like population found in WT mice is quite unclear at the moment.

Many thanks for your recent decision and for sending further comments of the reviewers. We have now included the following paragraph in the Discussion section in order to address the reviewer's concern.

"An important consideration is whether IMLEC is a normal population of hematopoietic cells or a population that arises after pathogenic mutations. \[...\] Further studies are needed to identify conditions that can lead to accumulation of IMLEC short of these known mutations."

We hope you will find these modifications satisfactory.
